Articles
-
All
-
Scientific Reviews
-
EDM
-
Blog
-
Most Recent
-
Oldest
-
SARS-CoV-2 contains four main structural proteins: spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins. All the proteins and subcellular structures of CoVs are promising targets for SARS-CoV-2 research.
-
The concept of ADC can be traced back to the early 1900s, It is a visionary magic bullet that could deliver a toxic drug to certain malignant cells without affecting other normal tissues. Now, it seems that a golden age of ADC drug development is coming.
-
PROTAC, which exploit the ubiquitin-proteasome pathway to specifically degrade target proteins. PROTACs not only solve the problem of undruggability but they also have other advantages compared to traditional drug targeting strategies.
-
PROTAC — Target Selection and Design
2022-07-08
A PROTAC molecule consists of three components: a target protein binding ligand, an E3 ligase ligand, and a linker connecting these two moieties. Here, we will discuss the conventional approaches for the rational design of PROTAC molecules. -
Organoids represent an important bridge between 2D cultures and in vivo mouse/human models. The organoid technology exerts enormous potential in evaluation of efficacy and toxicity of drugs, regenerative medicine, and precision medicine.In this article, we will briefly introduce organoid technology.
-
Development of Intestinal Organoid
2022-07-28
3D organoid is one of the revolutionary developments in biomedical field during the past 10 years. The establishment of intestinal organoids is an important milestone in the development of organoid technology. -
BacPROTACs is composed of a POI ligand, a chemical linker and a ClpCNTD anchor. BacPROTACs can induce in vitro and in vivo degradation of non-eukaryotic proteins in bacteria without the ubiquitin proteasome system.
-
RNA therapeutics have changed the landscape of drug development, which possess broader spectrum of drug targets, simplicity and efficiency in development and manufacturing.In this article, we will discuss the underlying mechanisms of RNA-based drugs on the market or in clinical stages.
-
Tsvetkov et al. published in Science and demonstrated a copper-induced programmed cell death — Cuproptosis. As a novel programmed cell death, excess copper triggers abnormal aggregation of lipoylated proteins in TCA cycle and clearance of Fe-S cluster proteins, ultimately leading to cell death.
-
A comprehensive explanation of ferroptosis
2022-09-15
Ferroptosis is a new type of RCD that depends on iron and characterized by the accumulation of lipid peroxides. In this article, we will pay our attention on ferroptosis and briefly discusses its mechanism. -
It's has been proved that p53, as a tumor suppressor gene and immune guardian, may become a destroyer through its own mutation. Moreover, the mechanism of p53 was found to be related to ferroptosis. This article mainly explores the mechanism between p53 and ferroptosis in detail.
-
Organoids have great potential in research of organ development, disease modeling, drug screening and, precision and regenerative medicin. In this article, we will expalin the origin of the organoids. Adult stem cells (ASCs) or pluripotent stem cells (PSCs) , which is the better choice.
-
Autophagy, derived from the Greek meaning "eating of self", plays an indispensable role in maintaining homeostasis. p27 is an inhibitor of cyclin CDKs, but how p27 regulates autophagy remains unknown. This article will cover the mechanism of autophagy and p27-related cell cycle regulation.
-
CMA (chaperone-mediated autophagy) plays an essential role in maintaining neuronal protein stability and preventing neurodegeneration. In this article, we will comprehensively clarify the role of CMA in the occurrence and development of neurodegenerative diseases.
-
TME (Tumor microenvironment) is considered as a complex integrated system, composed of cellular components such as tumor cells and immune cells, as well as non-cellular components such as ECM and cytokines. According to the spatial distribution of immune cells in TME, "hot" and "cold" TME will be explained in this article.
-
As powerful pain relievers, the opioids morphine and fentanyl have been "checked" by their side effects (listed as controlled substances). How to reduce its side effects? What is its mechanism? This research will explore its mechanism.
-
Efferocytosis is the process in which phagocytes remove programmed dead cells. It prevents secondary necrosis of dying cells from releasing harmful cell contents (such as oxides and proteases) that may cause inflammation. Here, we will introduce three stages of efferocytosis: Find, Eat, Digest.
-
Understanding the mechanism of aging not only has guiding significance for prolonging human life but also has important clinical significance for the prevention and treatment of diseases in the elderly population , thus, improving their life quality and well-being.
-
Mammalian cells can also photosynthesize like plants! Photosynthesis can improve cell anabolism and exhibit good clinical effect in degenerative diseases (osteoarthritis).
-
The latest study of Cell magazine "Neural mechanism underlying depressive-like state associated with social status loss" considers social factors as a breakthrough point. It has been found that the downward transition of social status induces depression-like behavior in mice whereas improves the depressive state by restoring their social environment.
-
PROTAC - Design Strategy for Targeting
2023-04-23
Protein degradation targeting chimera (PROTAC) is a technology that uses the ubiquitin proteasome pathway to silent target protein. However, PROTAC still has problems such as solubility, membrane permeability, and selectivity. In this article, we have summarized three strategies for optimization: light-controlled linker, PAC molecule, and specific E3 ligase. -
Necroptosis, also known as necroptosis, is a form of regulated necrotizing cell death mediated by RIP1 and RIP3 kinases. Necroptosis is a process that prevents the self-destruction of activated cells that are blocked by apoptosis. Necroptosis plays a tumor suppressor role in most cases. It may provide benefits in the researches of a variety of human diseases involving immune inflammation and cell death.
-
Stem cell classification and its application
2023-05-18
Stem cells (SCs) have the unique ability to self-renew and differentiate into different cell types. SCs can differentiate into various types of tissue cells under specific conditions. Additionally, they can be further cultured to form different tissues and organs in the human body. Stem cells have numerous applications in various fields, including cell therapy, organ transplantation, neurodegenerative disease modeling, and drug screening. -
Mitophagy:Mechanisms and Detection
2023-05-25
About 60 years ago, Christian de Duve first used the term "autophagy" to describe his observation of the degradation of mitochondria and other intracellular structures in lysosomes of rat liver. Over the years, autophagy has remained a beloved topic of research by the National Natural Science Foundation of China (NSFC).Today, let's talk about mitochondrial autophagy. -
Structure of Lipid Droplets
2023-06-15
Huh? Lipid droplets? Organelles? In the past, biological data usually only show the traditional organelles, such as mitochondria, Golgi apparatus, endoplasmic reticulum, etc., lipid droplets are often not mentioned by people. Today, we will make a systematic explanation of lipid droplets, so that everyone has a clear understanding! -
HLA-E, A Novel Immune Checkpoint
2023-06-29
Immune checkpoints have immunosuppressive functions. It can be used in the research of tumor immunotherapy. In this article, we introduce a new paper entitled "Immune checkpoint HLA-E: CD94 - NKG2Amediates evasion of circulating tumor cells from NK cell surveillance "research paper. -
Organoid Culture: Questions & Answers
2023-07-26
In the last issue, we conducted a live lecture on the theme of organoid culture. Today, we have a special topic to solve your doubts in the last live class! -
WHO's Q2 drug list has been updated. Let's take you through the list of the most noteworthy small molecule drugs that we should pay attention to.
-
FDA Approved Drug List!
2023-09-14
In the first half of 2023 (as of June 27), the FDA approved 26 new drugs, let's take you learn about it through the article. -
IHC is an indispensable technique for studying tissue morphology and in situ antigen expression, but usually only one or two antigens in tissues can be stained for analysis. It cannot judge the results more intuitively. Today, Little M will introduce you to the upgraded version mlHC.
-
A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening of diseases such as cancer, infectious diseases, and rare diseases.
-
FDA Annual Review | Record-breaking number of new drug approvals in 2023!
-
Are frozen cells always damaged? Is the survival rate of revived cells low? When is it appropriate to freeze cells? What should be considered when reviving them? Today, we're sharing a guide to avoid pitfalls in cell freezing and revival!
-
KRAS, a gene we've heard so much about, has quickly risen to fame after shedding its "undruggable" label. After reading numerous articles, it's easy to feel overwhelmed and wonder: What exactly should we know about this often-discussed but previously "undruggable" target KRAS?
-
Compound Screening Guide!
2024-03-15
How to use compound library? How to design an experiment if you buy a compound library? Want a specific experimental protocol? This article will introduce popular experimental techniques and provide new ideas for publishing high level literature. -
Wnt/β-catenin and tumor EMT
2024-03-18
Epithelial-Mesenchymal Transition (EMT) is closely related to the plasticity of tumor cells and is a necessary process for tumor metastasis. Wnt/β-catenin is one of the main actors involved in the EMT process. Today, we’re here to popularize the tumor EMT and Wnt/β-catenin pathway~ -
The 2024 AACR meeting concluded successfully in California, USA. Which antitumor drugs stole the show at this conference?
-
Katalin Karikó and Drew Weissman were awarded the Nobel Prize in Physiology or Medicine in 2023 for their groundbreaking work in nucleoside modification, which paved the way for the creation of successful mRNA vaccines to fight against COVID-19. Let's now delve into the complete process of mRNA vaccine development.
-
Science | A "new" mechanism for non-ubiquitinated Midnolin-proteasomal degradation pathway
2024-04-26
“ubiquitin-mediated protein degradation” won the Nobel Prize in Chemistry in 2004! In fact, proteasomes degrade not only ubiquitinated proteins but also non-ubiquitinated ones. The mechanism remains shrouded in mystery. After reading this piece today, you might have a lightbulb moment! -
Still struggling to find the preparation methods for various solutions? Save your time! Here comes a nanny-level tutorial!
-
STZ Induced Diabetes Models
2024-06-13
Spotlight: How can STZ Help Diabetes Research? -
Exosomes, which won the Nobel Prize in 2013, are still a research hotspot in the national natural sciences, and their popularity has only increased over the past decade (in 2022, they still rank 5th in the national natural sciences hotspots!). Why have exosomes become the darling of scientific research? Let's take a look together~
-
How important is the compound library? It connects to drug screening on one end and leads to lead compound modifications on the other, serving as one of the sources of new drug development.
-
Degrade target proteins through the autophagy-lysosome pathway including LYTAC, AUTAC, and ATTEC have gained increasing attention in recent years due to their significant research potential!
-
Antibodies!
2024-07-26
Today, We introduce antibodies for everyone! -
Science’s 2023 Breakthrough: GLP-1R Agonists
2024-08-13
GLP-1RAs, which achieved great success in 2023 and draws people’s attention back to obesity treatments and GLP-1 therapies worldwide, was chosen as the breakthrough of year 2023 by Science [2]. -
What Are Popular Anti-tumor Drug Targets?
2024-08-20
The rapid development of targeted anti-cancer drugs has spurred diverse research across various modalities. These include small molecules, monoclonal antibodies (mAbs), cell immunotherapies, antibody-drug conjugates (ADCs), and PROTACs (proteolysis targeting chimeras). -
Cuproptosis, How much do you know?
2024-08-22
Cells die in a variety of ways, including apoptosis, pyroptosis, necrosis, and ferroptosis......And, of course, cuproptosis. So, how much do you know about cuproptosis? -
Virtual Screening and New Uses for Old Drugs
2024-09-17
With the advancement of medical science, drug screening against various disease targets has become the fundamental strategy for drug development. Currently, computer-based virtual screening techniques are emerging in the field of new drug research due to their efficiency and low cost. Let's explore it today! -
Recently, Mol Cell reported the discovery of the first ferroptosis marker, Hyperoxidized PRDX3! Let’s take a look together~
-
Cuproptosis's Knowledge Points!
2024-09-25
With the establishment of the cuproptosis mechanism related research has attracted more and more attention from major journals. Expect to use the sharp sword of cuproptosis to stab the tumor cells. -
2024 Nobel Prize Announcements! Curious about the details? Click to dive into the exciting developments!
-
How they used PKH 26 for cellular studies?
2024-10-21
We are thrilled to highlight our client study using PKH 26 (MedChemExpress) , a red fluorescent dye that has proven invaluable for in vitro cell labeling and tracing. This innovative research, published in the Journal of Nanobiotechnology. -
Delve into the intricate networks that govern mitochondrial quality control. By examining key mechanisms such as biogenesis, mitochondrial dynamics (fission and fusion), proteolysis, and mitophagy.
-
Unlocking the Power of Intermittent Fasting: The 16+8 Method
-
We are thrilled to share the latest advancements in AI technology as highlighted in this insightful article. From groundbreaking innovations to transformative applications, the future of AI is brighter than ever!
-
Advancing Chronic Kidney Disease Research with GJ103 and Lamin B1 Antibody!
-
When you hear "inflammation" and "DNA damage," you might immediately think of disease or injury. However, in brains, these two processes are key steps in forming long-term memories, particularly related to specialized cells in our brain called hippocampal neurons.
-
Autophagy is a fundamental process that degrades various components within the cell.
-
This article will tell you about the common methods of modeling liver disease in animal models.
-
nside cells, the homeostasis and degradation of proteins is a precisely regulated process. If proteins cannot be degraded in time, it may lead to the occurrence of various diseases such as neurodegenerative diseases and cancer. This article will tell you the process of how proteins are recognized, labeled and then degraded!
-
This article will walk you through the remarkable impacts of anti-payload antibodies, delving into how these molecules are revolutionizing drug development and biological research!
-
This article introduces some common cardiovascular disease models, inducers, modeling protocols and successful modeling cases in the research.
-
Do you feel confused when you start culturing cells? This article will show you the basic methods and steps of cell culture!
-
Cell Migration vs. Invasion: Differences Revealed by Scratch Assays and Transwell Experiments
2025-05-30
In scientific research, cell migration and invasion are crucial for understanding many important biological processes. This article delves into commonly used detection methods: the scratch assay and Transwell migration/invasion assay. -
How should drug screening experiments be conducted? How can we ensure the accuracy of the lead compounds identified? This article will take you through how MCE's clients conduct drug screening experiments.
-
In this issue, we will conduct an in-depth interpretation from the dimensions of nanoparticle design, mechanism of action, in vivo and in vitro efficacy, and immune regulation, revealing how this research brings new hope for the treatment of invasive tumors through interdisciplinary innovation!
-
IHC, ICC, IF Techniques: A Practical Guide
2025-07-25
Confused About IHC/ICC/IF? Why Does Immunostaining Seem So Complicated? Read This Now! Master Immunostaining with Confidence! -
HTS Breakthroughs Powered by MCE Libraries
2025-08-13
Key High-Throughput Screening Breakthroughs of 2024 Featuring MCE -
The article introduces the mechanisms of ROS generation and the methods for their detection.
-
Have you ever noticed that after staying up late, your appetite—especially for high-calorie foods—gets out of control? If this sounds familiar, today’s article might offer some good news.
-
Encountering challenges with the high costs and long timelines of drug screening? Have a defined target but remain uncertain how to efficiently identify active molecules? Unsure how to validate hits generated from virtual screening? The ‘Winning Combination’ of drug screening offers a powerful solution to address these critical obstacles.
-
Generating Stable Cell Lines with Lentivirus
2025-09-16
A step-by-step protocol of establishing stable cell lines using lentivirus -
A groundbreaking study in Nature Communications reveals the key mechanism behind Idiopathic Pulmonary Fibrosis and identifies an existing drug with the potential to counter it.
-
This detailed guide outlines the standardized experimental protocols for multiplex immunohistochemistry (mIHC), systematically summarizes common technical issues encountered during sample preparation, staining and imaging processes, and provides practical troubleshooting solutions to ensure reliable and reproducible results in biomedical research and clinical sample analysis.
-
Finding adipogenic induction media too expensive and tricky to prepare? This comprehensive guide to 3T3-L1 adipogenic differentiation simplifies the process, helping you achieve great results!
-
Microglia– the only immune cells within the brain parenchyma. With advancements in imaging technologies, people’s understanding of microglia has shifted from being viewed as 'resting' cells to 'highly active' cells, particularly due to their dynamic processes that seem to be probing surrounding tissues and monitoring neuronal activity. This has made microglia a focal point of research in the field of neuroscience.
-
Exosomes—natural nanoscale carriers—are revolutionizing targeted therapy. This article uncovers the science behind their precision in drug delivery.
-
Cracking the PROTAC Permeability Barrier: CD36-Mediated Endocytosis as a Potential Breakthrough
2025-12-03
This article provides an in-depth analysis of cutting-edge literature revealing CD36 as a key mediator of cellular uptake for PROTACs and bRO5 compounds. By structurally optimizing PROTAC molecules to enhance their affinity for CD36, membrane permeability can be markedly improved, leading to significantly enhanced antitumor efficacy. -
Efficient Generation of Mouse Small Intestinal Organoids: A Complete Experimental Protocol Guide
2025-12-10
How to successfully create mouse small intestine organoids? A detailed, hands-on guide to the entire process, all in one article! -
A November 2025 Cell study discovers Mitoxyperilysis, a new mTOR-regulated, caspase-independent cell death pathway driven by innate immune and metabolic dysregulation via mitochondrial-plasma membrane contact and oxidative damage, and verifies its potential to induce tumor necrosis for cancer therapy with key regulators including BAX, BAK1 and BID.
-
This paper elaborates on cytokines for culturing major immune cells, their regulatory roles, recombinant cytokines' merits and MCE’s related high-quality products.
-
In the hunt for the next ‘GLP-1,’ amylin therapeutics, which have shown strong weight-loss results in clinical trials, have become a major focus for both multinational pharma and the scientific community.
-
Essential for High-Impact Papers: Present Your CCK-8 Experimental Results in a More Outstanding Way!
2026-03-18
CCK-8 is a widely used WST‑8‑based reagent for cell proliferation and cytotoxicity assays. It features high sensitivity, reliable results and easy operation, and is applicable to cell viability analysis, drug screening and growth inhibition testing. -
This article walks you through the experimental design and workflow of flow cytometry, delivering a clear, dynamic, and professional overview to elevate your research.
-
Molecular glue degraders have evolved from a serendipitous observation to one of the most dynamic and transformative fields in biomedical research.
-
GLP-1 and Obesity Research
2026-08-14
Obesity substantially increases the risk of chronic diseases such as T2D and cardiovascular disease. The breakout success of GLP-1 therapies has spotlighted GLP-1R and a wave of emerging obesity targets. -
Research Solution for Breast Cancer TME
2025-05-21
This review examines the complex interactions within the breast cancer tumor microenvironment, emphasizing how understanding these dynamics is essential for developing effective therapies and overcoming immune resistance. -
This review discusses the fundamentals of lipid biology and lipid metabolism, examines dysregulated lipid metabolism in cancer, and summarizes therapeutic strategies targeting lipid metabolic pathways.
-
This review critically examines the role of the JAK-STAT pathway in immunity and autoimmune diseases, reviews current clinical applications of targeted therapies, and highlights emerging trends in autoimmune drug development.
-
This review presents an overview of antibody–drug conjugates from design principles and antitumor mechanisms to structural innovations, clinical progress, and future development prospects.
-
This review explores mechanisms and strategies for modulating the gut microbiota to enhance cancer immunotherapy, providing insights to improve therapeutic efficacy.
-
Combating Immune Evasion in Cancer
2025-10-15
This review summarizes the mechanisms by which tumors evade immune surveillance and discusses therapeutic strategies to restore antitumor immunity. -
This review summarizes the mechanisms of drug resistance in triple-negative breast cancer and highlights emerging therapeutic strategies.
-
Bispecific Antibodies in Cancer Therapy
2025-10-29
This review highlights the mechanisms, technology platforms, and clinical progress of bispecific antibodies, and discusses emerging strategies to guide future development. -
This review provides insights into the pancreatic ductal adenocarcinoma tumor microenvironment, highlighting its cellular composition, stromal heterogeneity, and immune-targeting strategies.
-
This review outlines macrophage functions and classification, and provides practical experimental guidelines for macrophage differentiation, polarization, and identification.
-
Understanding In Vivo CAR-T Cell Therapy
2026-01-22
This review provides a comprehensive overview of in vivo CAR-T therapy, covering technical platforms, clinical translation, and key challenges such as gene delivery and immunogenicity. -
Highlight single-cell metabolomics and stable isotope tracing (SIT) in uncovering metabolic heterogeneity and nutrient flux dynamics in tumors.
-
Explore ADC evolution, immune combination strategies, and clinical advances at the intersection of targeted therapy and immunotherapy.
-
Tumor Organoid-Immune Cell Co-Culture Models: Advances, Applications, and Future Directions
2026-05-07
Summarize technical strategies, application advances, and future directions of tumor organoid–immune co-culture systems. -
Review mechanisms, major challenges, and efficacy-enhancing strategies of TCR-T therapy in solid tumors, with implications for future research and clinical translation.
-
The Dual Role of Cellular Senescence in Cancer: Mechanisms, Microenvironment, and Therapeutics
2026-05-21
Explore the dual role of cellular senescence in cancer, including tumor suppression, SASP-driven tumor promotion, senescence heterogeneity and plasticity, and advances in senescence-targeted therapies. -
Explore lysosomal nutrient sensing, quality control, cellular adaptation, disease mechanisms, and emerging therapeutic approaches.
-
Breaking Immune Resistance in Colorectal Cancer: From Molecular Mechanisms to Precision Therapy
2026-06-25
Explore CRC molecular subtypes, immune landscapes, resistance mechanisms, and emerging precision strategies for improving outcomes across distinct subtypes. -
Explore the mechanisms driving immune tolerance breakdown in autoimmune diseases and emerging tolerance-restoring strategies, with a focus on IL-2-based immune modulation.
-
Explore the mechanisms of tumor immune evasion, dynamic checkpoint regulation, and the evolution of mechanism-driven combinations and patient stratification.
-
Explore how mitochondrial quality control, inflammatory signaling, and metabolic–epigenetic reprogramming regulate cellular senescence and the SASP, along with strategies to restore mitochondrial homeostasis.
-
EC0489, a SMDC for Cancer Therapy
2019-03-25
EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a SMDC under development for the treatment of solid tumours. -
R916562, a dual Axl/VEGF-R2 inhibitor, could be a potential anti-angiogenic and anti-metastatic drug for cancer chemotherapy.
-
Role of PRMT7 Probe SGC3027 in Cancer
2019-03-27
SGC3027 is the first potent, selective and cell active chemical probe for PRMT7. SGC3027 is also a pro-drug, which converts to the active compound SGC8158 -
Alofanib, An Allosteric Inhibitor of FGFR2
2019-03-28
Alofanib is an allosteric inhibitor of FGFR2 and inhibits FGF-mediated proliferation with GI50s of 16-370 nM, showing pronounced antitumor activity. -
A Novel and Efficacious RAF Inhibitor RAF709
2019-03-30
RAF709, a novel and efficacious RAF inhibitor, activates the MAPK pathway and shows antitumor activity in tumor cells harboring BRAF or RAS mutations. -
CF53 is a highly potent, selective and orally active inhibitor of BET protein, with anti-tumor activity in acute leukemia and breast cancer cell lines.
-
AZD3229 is a Potent Pan-KIT Mutant Inhibitor
2019-04-04
AZD3229 is a potent, pan-KIT mutant inhibitor with potent single digit nM growth inhibition against a diverse panel of mutant KIT driven Ba/F3 cell lines. -
BR351 is a Brain Penetrant MMP Inhibitor
2019-04-05
BR351 is a brain penetrant MMP inhibitor, and a potential tool for the molecular imaging of activated MMPs with PET, with an IC50 in the nanomolar range. -
A Lead PROTAC BRD9 Chemical Degrader
2019-04-06
PROTAC BRD9 Degrader-1 is a lead PROTAC BRD9 chemical degrader and a selective probe useful for the study of BAF complex biology. -
SGC-GAK-1 is a potent, selective, and cell-active GAK inhibitor and shows potent anti-proliferative activity in LNCaP and 22Rv1 cells.
-
COH000 is an allosteric, covalent and irreversible inhibitor of SUMO-activating enzyme, with an IC50 of 0.2 μM for SUMOylation in vitro.
-
MK-0429 is An Oral Integrin (αvβ3) Inhibitor
2019-04-11
MK-0429, an orally active αvβ3 inhibitor, is a potential therapeutic agent for the prevention of kidney fibrosis, melanoma and osteoporosis. -
AZ304, a Dual BRAF Inhibitor Against Cancer
2019-04-12
AZ304 is a potent BRAF inhibitor, blocks both wild type BRAF and V600E mutant BRAF activity, with IC50s in the nanomolar range. -
IITZ-01 is a potent lysosomotropic autophagy inhibitor with single-agent antitumor activity, with an IC50 of 2.62 μM for PI3Kγ.
-
Erteberel is a Selective ERβ Agonist
2019-04-16
Erteberel (LY500307) is a synthetic, nonsteroidal estrogen which acts as a selective ERβ agonist and under development for the treatment of schizophrenia. -
MBQ-167 is a dual Rac/Cdc42 inhibitor in in metastatic cancer, with IC50s of 103 nM for Rac 1/2/3 and 78 nM for Cdc42 in MDA-MB-231 cells, respectively.
-
PRN1008 is a Reversible Covalent and Oral Active Inhibitor of Bruton’s Tyrosine Kinase (BTK)
2019-04-18
PRN1008 is a selective, reversible covalent and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK), with an IC50 of 1.3 nM. -
Multiple Tyrosine Kinases Inhibitor TAS-115
2019-04-19
TAS-115 is a potent VEGFR and c-Met/HGFR-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively. -
Y06036 is a potent and selective BET inhibitor for potential treatment of castration-resistant prostate cancer. With nanomolar inhibition.
-
JNJ-64619178 is a selective and pseudo-irreversible PRMT5 inhibitor with an IC50 of 0.14 nM. Has potent Activity In Lung Cancer.
-
(E)-AG 99 is an EGFR inhibitor and shows a growth-inhibition on not only serum-starved cells but also normally grown cells. Treatment for Bladder cancer.
-
BTR-1 potently inhibits cell growth. It induces S phase arrest, affects DNA replication. Dose-dependently induces cytotoxicity in leukemic cell lines.
-
TAK-828F is a potent, selective and orally active retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist. TAK-828F inhibits IL-17A cytokine expression and reduces symptoms of autoimmune encephalomyelitis mice.
-
Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM. Antitumor activity.
-
Borussertib is a covalent-allosteric and first-in-class inhibitor of protein kinase Akt, with an IC50 of 0.8 nM and a Ki of 2.2 nM for Akt-wt.
-
NRX-252262 is a β-catenin:β-TrCP interaction enhancer, and its cognate E3 ligase, SCFβ-TrCP, induces mutant β-catenin degradation, with an EC50 of 3.8 nM
-
TAK-981 is a selective inhibitor of the SUMOylation enzymatic cascade, with potential immune-activating and antineoplastic activities
-
TD-428 is a Highly Specific BRD4 Degrader
2019-04-29
TD-428, a immunomodulatory drug analog, is a highly specific BRD4 degrader with a DC50 of 0.32 nM. TD-428 reduces c-Myc levels more efficiently than JQ1. -
SLLN-15 is an oral activ enhancer of autophagy that activates cytostatic macroautophagy/autophagy in triple-negative breast cancer (TNBC).
-
A1874 is a nutlin-based and BRD4-degrading PROTAC with a DC50 of 32 nM. Effective in inhibiting many cancer cell lines proliferation
-
BAY-8002 is a selective and orally active inhibitor of monocarboxylate transporter 1 (MCT1), with an IC50 of 85 nM. Has potential to treat lymphoma.
-
MRTX-1257 is a selective, irreversible, covalent and oral active KRAS G12C inhibitor, with an IC50 of 900 pM for KRAS dependent ERK phosphorylation.
-
USL311 is a selective CXCR4 antagonist, which prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4. Anti-tumor activity.
-
TX1-85-1, a ATP-competitive ligand of Her3, covalent modification of Her3 to inhibit Her3 signaling
2019-06-01
TX1-85-1 is a Her3 (ErbB3) inhibitor with an IC50 of 23 nM. TX1-85-1 induces partial degradation of Her3 protein and attenuates Her3-dependent signaling. -
IWP-O1, a Highly Potent Porcupine Inhibitor, Functions by Preventing the Secretion of Wnt Proteins
2019-06-03
IWP-O1 is a Porcupine (Porcn) inhibitor, with an EC50 of 80 pM in L-Wnt-STF cells. IWP-O1 functions by preventing the secretion of Wnt proteins[ -
PF-06465469 is a Covalent Inhibitor of ITK
2019-06-08
PF-06465469 is a potent and covalent inhibitor of ITK with an IC50 of 2 nM. PF-06465469 inhibits MEK1/2 or AKT phosphorylation. -
JMS-17-2 is a CX3CR1 Antagonist
2019-06-12
JMS-17-2 is a potent and selective CX3CR1 antagonist with an IC50 of 0.32 nM. Has potential to treat cancers such as breast cancer. -
Ralimetinib (LY2228820) is a selective and ATP-competitive inhibitor of p38 MAPK α/β, with IC50s of 5.3 and 3.2 nM, respectively. Anti-tumor activity.
-
BAY-11-7082 inhibits the proliferation and induces the apoptosis of U266 cells through inhibiting NF-κB pathway. BAY 11-7082 ameliorates experimental diabetic neuropathy by modulating neuroinflammation and improving antioxidant defence.
-
S130, Targeting ATG4B, Inhibits Autophagy and Activates Apoptosis in Colorectal Colon Cancer
2019-06-19
S130 is a high affinity, selective inhibitor of ATG4B (a major cysteine protease) with an IC50 of 3.24 µM. S130 suppresses autophagy flux. -
S18-000003 is a potent, selective and orally active inhibitor of retinoic acid receptor-related orphan receptor-gamma-t (RORγt). S18-000003 ameliorates psoriasis-like lesions in vivo. S18-000003 can be used for the research of skin inflammatory diseases.
-
PTC299 is a dual and orally active DHODH and VEGF inhibitor, has broad and potent activity against hematological cancer cells.
-
AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3). AMG 487 has potential to treat metastatic cancer.
-
MRT67307, a dual IKKε/TBK1 inhibitor, inhibits ULK1 and ULK2 with IC50s of 45 and 38 nM, respectively. MRT67307 blocks mTOR-dependent autophagy.
-
CCT020312, the G1/S checkpoint activator, is a selective EIF2AK3/PERK activator. CCT020312 elicits EIF2A phosphorylation in cells.
-
SBI-0206965 is a selective and cell permeable autophagy kinase ULK1 inhibitor with IC50s of 108 nM for ULK1 and 711 nM for the highly related kinase ULK2 .
-
FGTI-2734 is a dual farnesyl and geranylgeranyl transferase-1 inhibitor. FGTI-2734 prevents membrane localization of KRAS and mutant KRAS pancreatic tumors.
-
CA-5f is a potent late-stage macroautophagy (autophagy) inhibitor via inhibiting autophagosome-lysosome fusion. CA-5f increases LC3B-II and SQSTM1 protein.
-
BI-882370 is a potent RAF kinase inhibitor with IC50s of 0.4, 0.8, and 0.6 nM for oncogenic BRAFV600E-mutant, the WT BRAF and CRAF kinases , respectively.
-
MSX-122 is an orally active partial antagonist of CXCR4, inhibiting CXCR4/CXCL12 actions. MSX-122 has both anti-tumor and anti-metastasis activities.
-
ZT-12-037-01 is a ATP-competitive and specific STK19 inhibitor and inhibits oncogenic NRAS-driven melanocyte malignant transformation.
-
PT2977 is an orally active and selective HIF-2α inhibitor with an IC50 of 9 nM. PT2977 is a potential treatment for ccRCC and VHL disease.
-
BI-2852 is a potent KRAS inhibitor with nanomolar affinity and reduces pERK and pAKT levels in a dose-dependent manner in a KRAS mutant cell line NCI-H358.
-
BAY-293 is a potent inhibitor of Son of Sevenless 1 (SOS1) and blocks RAS activation via disruption of the KRAS-SOS1 interaction with an IC50 of 21 nM.
-
WZ811 is an Orally Active CXCR4 Antagonist
2019-09-07
WZ811 is an orally active, highly potent competitive antagonist of CXCR4, which inhibits chronic lymphocytic leukemia progression and tumorigenesis. -
RU-302 is a pan-TAM inhibitor that blocks the TAM Ig1 ectodomain and the Gas6 Lg domain interaction. RU-302 blocks Gas6-inducible Axl receptor activation.
-
BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor and sensitizes apoptosis by in breast cancer.
-
IPR-803 is a potent inhibitor of the uPAR•uPA protein-protein interaction, and binds directly to uPAR with sub-micromolar affinity.
-
Vorolanib is an orally active, multikinase VEGF/PDGF receptor inhibitor with antitumor activity and is expected to disrupt tumor angiogenesis.
-
CCG-222740 is a potent and selective MRTF pathway inhibitor. It effectively reduces fibrosis in the skin and blocks melanoma metastasis.
-
IACS-8803 is a highly potent cyclic dinucleotide stimulator of interferon genes (STING) agonist with robust systemic antitumor efficacy.
-
AC-73 is a first specific, orally active the cluster of differentiation 147 (CD147) inhibitor and specifically disrupts CD147 dimerization.
-
CH6953755 is a potent, orally active and selective YES1 kinase inhibitor leading to antitumor activity against YES1 Gene -amplified cancers.
-
CA-4948 is a Selective and Orally Bioavailable IRAK4 Kinase Inhibitor for Lymphoma Treatment
2020-01-05
CA-4948 is a potent, selective and orally bioavailable IRAK4 kinase inhibitor. CA-4948 can be used for the treatment of lymphoma. -
GPP78 is a potent Nampt inhibitor. GPP78 is cytotoxic to neuroblastoma cell line SH-SY5Y cells. GPP78 has anti-cancer and anti-tumor activity.
-
ADH-503 is an orally active and allosteric CD11b agonist and leads to the repolarization of tumor-associated macrophages.
-
Balixafortide is a potent, selective peptidic CXCR4 antagonist with anti-cancer effects, and blocks β-arrestin recruitment and calcium flux.
-
CCT365623, an Orally Active LOX Inhibitor, Supresses EGFR (pY1068) and AKT Phosphorylation
2020-04-16
CCT365623 is an orally active LOX inhibitor, suppresses EGFR (pY1068) and AKT phosphorylation driven by EGF. CCT365623 has good pharmacokinetic properties. -
RBN-2397 is an orally active accross species NAD+ competitive inhibitor of PARP7. RBN-2397 binds to PARP7 and restores interferon (Type I) signaling.
-
HM03 is a potent and selective HSPA5 inhibitor with anticancer activity. HSPA5 plays a key role in monitoring protein transport through the cell.
-
GSK143 is an orally active and highly selective spleen tyrosine kinase (SYK) inhibitor. GSK143 reduces inflammation in the intestinal muscularis in mice.
-
GSK621 is a potent and specific AMPK activator and induces autophagy and apoptosis in acute myeloid leukemia (AML) cells.
-
EW-7195 is a potent and selective ALK5 inhibitor, and efficiently inhibits TGF-β1-induced Smad signaling, EMT and breast tumour metastasis to the lung.
-
MSA-2 is an orally available non-nucleotide STING agonist. MSA-2 shows antitumor activity and stimulates interferon-β secretion in tumors.
-
SP-8356, an orally active CD147inhibitor, exerts anti-breast cancer effects by inhibiting NF-κB signaling. Anti-atherosclerotic effects.
-
CB-1158, a potent and orally bioavailable inhibitor of arginase, blocks myeloid cell-mediated immune suppression in the tumor microenvironment.
-
SRX3207 is an orally active and first-in-class dual Syk/PI3K inhibitor. SRX3207 possesses effective anti-tumor activity in vitro and in vivo.
-
Verucopeptin inhibits v-ATPase activity by directly targeting the v-ATPase ATP6V1G subunit but not ATP1V1B2 or ATP6V1D. Also a potent HIF-1 inhibitor.
-
E7820, sulfonamide derivative, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium.
-
Cyclo(-RGDfK) is a selective inhibitor of the αvβ3 integrin. Cyclo(-RGDfK) potently targets cancer cells through binding to the cell surface αvβ3 integrin.
-
Cilengitide is a compound targeting angiogenesis, the cornerstone of tumor growth and metastasis. ανβ3 and ανβ5 are the target of Cilengitide.
-
Tetrac inhibits the cellular actions of thyroid hormone initiated at the hormone receptor on plasma membrane integrin alphavbeta3.
-
ENMD-1198 is an orally active microtubule-targeting agent with antiproliferative and antiangiogenic activity.
-
CC-90001 is a potent, selective, and orally active inhibitor of JNK. CC-90001 can be used for the research of idiopathic pulmonary fibrosis (IPF).
-
TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM).
-
YUM70 inhibits GRP78. Induces endoplasmic reticulum stress-mediated apoptosis. Pancreatic cancer. Acts as a novel anticancer agent.
-
FAPI-46 is a quinoline-based FAP-targeted radiotracer. FAPI-46 has higher tumor uptake and prolonged tumor accumulation.
-
LYN-1604 is a Potent ULK1 Activator
2021-04-24
LYN-1604, a potent ULK1 activator, induces cell death involved in ATF3, RAD21, and caspase3, accompanied by autophagy and apoptosis. -
BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction. It induces high levels of IL-2.
-
ML339 is a Selective CXCR6 Antagonist
2021-05-12
ML339 is a small molecule antagonist would block Prostate cancer cell trafficking; hence mediate a metastatic event and disease progression. -
Butaprost is a selective prostaglandin E receptor (EP2) agonist. Butaprost can effectively mitigate kidney fibrogenesis in various fibrosis models.
-
Sitravatinib (MGCD516) is an Orally Bioavailable RTK Inhibitor with PD-1 Blockade Activity
2021-06-03
Sitravatinib, a small molecule RTK inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma. -
Motesanib (AMG 706) is an orally active VEGFR inhibitor. Potently inhibits angiogenesis and induces regression in tumor xenografts.
-
EMD527040 is a highly selective αvβ6 antagonist with antifibrotic activities.
-
Inupadenant is an orally active, highly selective A2A receptor antagonist with potent anti-tumor activity.
-
UK122 is a potent and selective urokinase-type plasminogen activator (uPA) inhibitor with anti-cancer activity.
-
AZD4635 is a potent, selective and orally active antagonist of A2AR that reverses adenosine-mediated immune suppression.
-
Nintedanib a potent and orally active triple vascular kinase inhibitor for VEGFR1/2/3, FGFR1/2/3 and PDGFRα/β.
-
Axitinib is a multi-targeted tyrosine kinase inhibitor and potently inhibitor VEGFR1, VEGFR2, VEGFR3 and PDGFRβ.
-
Spautin-1 is a specific and potent autophagy inhibitor which inhibits ubiquitin-specific peptidases, USP10 and USP13.
-
Alda-1 is a potent ALDH2 Agonist
2021-12-30
Alda-1 ameliorates H2O2-induced Achilles tendinopathy. Alda-1 could be used for preventing Achilles tendinopathy. -
CL097 is a TLR7/8 agonist. CL097 induces pro-nflammatory cytokines. CL097 induces NADPH oxidase priming and efficient diabetogenic cytotoxic T lymphocyte (CTL) function in NOD mice.
-
Indoximod, an immunometabolic adjuvant, is an orally active IDO pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR.
-
Tanomastat is an orally active, non-peptidic biphenyl MMPs inhibitor, with antiangiogenic, anti-invasive and antimetastatic activities.
-
AUTAC2 is a FKBP12-targeting autophagy-mediated degrader (AUTAC). AUTAC2 contains an FBnG and an SLF moiety.
-
BM213 is a selective C5aR1 agonist. It’s a useful research tool to study C5aR1 function
-
Telatinib is an orally active inhibitor of VEGFR2, VEGFR3, PDGFα, and c-Kit.
-
Marimastat (BB2516) is a broad spectrum and orally bioavailable inhibitor of MMPs (Matrix metalloproteinases).
-
Gardiquimod is a TLR7/8 agonist and can inhibit HIV-1 infection.
-
Vatalanib is an inhibitor of VEGFR2/KDR. Vatalanib induces inhibition of the angiogenic response to VEGF and PDGF.
-
Toceranib is a selective and orally active inhibitor of RTK and has the potential for the research of canine mast cell tumors.
-
Tiragolumab is an immune checkpoint inhibitor binding to TIGIT. Tiragolumab is effective against multiple solid malignancies.
-
Henatinib is an orally active small-molecule multikinase inhibitor that has demonstrated broad and potent antitumor activities.
-
KGP94 is a selective inhibitor of cathepsin L. KGP94 has antitumor activity and improves survival of bone metastases bearing mice.
-
Certepetide is a Tumor-penetrating Enhancer via RGD Motif Interaction with Alphav-integrins
2022-09-01
Certepetide is a tumor-penetrating enhancer and has the potential for the research of metastatic pancreatic ductal adenocarcinoma. -
BSP16 is a potent, orally active stimulator of interferon genes (STING) agonist. BSP16 has potent anti-cancer activity.
-
Parsatuzumab (RG 7414) is a humanized monoclonal antibody, that acts as an immunomodulator, and binds to EGFL7.
-
Serplulimab is a humanized monoclonal anti-PD-1 antibody and has the potential for the research of small cell lung cancer.
-
ABT-510, a peptide analog of thrombospondin-1 (TSP-1), can block angiogenesis in vitro and in vivo, and slow tumor growth.
-
Mogamulizumab is an Anti-CCR4 monoclonal antibody. It enhances antibody-dependent cellular cytotoxicity and is effective against leukemia.
-
Bapotulimab (BAY-1905254) is an ILDR2 IgG antibody that blocks the immunosuppressive effects of ILDR2 on T-cell activation.
-
Nanrilkefusp alfa is a selective and strong IL-15 agonist. It inhibits tumor metastasis and viability by activating natural killer (NK) cells.
-
Coibamide A is an N-methyl-stabilized cytotoxic depsipeptide with antiproliferative activity. Coibamide A induces autophagosome accumulation.
-
Urabrelimab (SRF231) is an anti-CD47 monoclonal antibody, blocking the CD47-SIRPα interaction. It has the potential to research anticancer.
-
Efineptakin alfa (NT-17) is a Long-Acting Recombinant Human IL-7 for Glioblastoma Research
2023-02-07
Efineptakin alfa (NT-17) is a long-acting recombinant human IL-7. Efineptakin alfa can be used for glioblastoma research. -
Pegdinetanib (BMS-844203) is a selective VEGFR-2 inhibitor with antitumor activity.
-
Tifcemalimab, a Humanized anti-BTLA monoclonal antibody, blocks the interaction of HVEM-BTLA by binding to BTLA and activates lymphocytes.
-
Geptanolimab (CBT-501) is a programmed death-1 (PD-1) monoclonal antibody. Geptanolimab can be used in research forsolid tumor research.
-
Dazostinag is a STING Agonist and Can be used for Antibody-Drug Conjugates (ADCs) Synthesis
2023-03-13
Dazostinag is a STING agonist and a playload, to synthesis antibody-drug conjugates (ADCs). It has antitumor activity in vivo. -
BBO-11818 is a potent, selective, orally bioavailable, and noncovalent pan-KRAS inhibitor targeting multiple clinically relevant KRAS mutants in both ON and OFF states.
Products
-
All
-
Inhibitors & Agonists
-
Isotope-Labeled Compounds
-
Fluorescent Dye
-
Peptides
-
Recombinant Proteins
-
Antibodies
-
Screening Libraries
-
Kits
-
Inhibitory Antibodies
-
Reference Standards
-
GMP Small Molecules
-
Enzyme
-
Biochemical Assay Reagents
-
Natural Products
| Cat. No. | Product Name | Information | Application | Publication |
|---|---|---|---|---|
| HY-L022 | FDA-Approved Drug Library |
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.
MCE owns a unique collection of 3,236 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE FDA-Approved Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.
|
|
195
|
| HY-50912 | Plerixafor octahydrochloride |
Plerixafor octahydrochloride (AMD3100 octahydrochloride) is a selective CXCR4 antagonist with an IC50 of 44 nM.
|
Pancreatic Cancer
Viral Infection
Digestive System Inflammation
Glucose Metabolism
SARS-CoV-2 Infection
Lung Fibrosis
Rheumatoid Arthritis
|
112
|
| HY-10046 | Plerixafor |
Pancreatic Cancer
Viral Infection
Digestive System Inflammation
Glucose Metabolism
SARS-CoV-2 Infection
Lung Fibrosis
Rheumatoid Arthritis
|
112
|
|
| HY-L035 | Drug Repurposing Compound Library |
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved and clinical drugs, especially after phase I drugs, have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing.
MCE Drug Repurposing Compound Library contains 5,148 approved drugs and passed phase Ⅰclinical drugs, which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties.
|
|
109
|
| HY-L031 | Small Molecule Immuno-Oncology Compound Library |
Immuno-Oncology is a type of immunotherapy that has the specific purpose of treating cancer. It works by stimulating our immune system to fight back. Normally, our immune system is able to destroy cancer cells in our body, however sometimes cancer cells can adapt and mutate, effectively hiding from our immune system. This is when tumors can develop and become a threat to our health. Immuno-oncology involves mobilizing lymphocytes to recognize and eliminate cancer cells using the body’s immune system. There are several immuno-oncology treatments available, including Immune cell therapy (CAR-T), monoclonal antibodies (mABs) and checkpoint inhibitors, cytokines and cancer vaccines.
MCE Small Molecule Immuno-Oncology Compound Library offers 831 bioactive tumor immunology compounds that target some important checkpoints such as PD1/PD-L1, CXCR, Sting, IDO, TLR, etc. This library is a useful tool for Immuno-oncology research.
|
|
88
|
| HY-L017 | Stem Cell Signaling Compound Library |
Adult stem cells are important for tissue homeostasis and regeneration due to their ability to self-renew and generate multiple types of differentiated daughters. Self-renewal is reflected by their capacity to undergo multiple/limitless divisions. Several signaling pathways are involved in self-renewal of stem cells, that is, Notch, Wnt, and Hedgehog pathways or Polycomb family proteins. Recent studies mainly focus on cancer stem cell (CSCs), induced pluripotent stem cell (iPSCs), neural stem cell and maintenance of embryonic stem cell pluripotency. Among them, CSCs have been believed to be responsible for tumor initiation, growth, and recurrence that have implications for cancer therapy.
MCE owns a unique collection of 2,931 compounds that can be used for stem cell regulatory and signaling pathway research.
|
|
86
|
| HY-L904 | Drug Fragment Library |
The MCE 1K Drug Fragment Library consists of 1,394 drug fragments. These drug fragments are derived from 2,946 FDA-approved drug molecules, and fragments from one drug can appear in other drugs, so these fragments are somewhat correlated with good PK/PD properties. Fragment-based screening can reserve enough chemical space for subsequent structural optimization. This compound library is an essential tool for drug screening based on FBDD (Fragment-Based Drug Discovery).
|
|
85
|
| HY-L053 | NMPA-Approved Drug Library |
From target identification to clinical research, traditional drug discovery and development is a time-consuming and costly process, which also bears high risk. Compared with traditional drug discovery, drug repositioning or repurposing, also known as old drugs for new uses can greatly shorten the development cycle and reduce development cost, which has become a new trend of drug development. After undergoing clinical trials, approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety, which can greatly improve the success rate of drug discovery. A number of successes have been achieved, such as metformin for type 2 diabetes and thalidomide for leprosy and multiple myeloma, etc.
MCE provides a unique collection of 1,534 China NMPA (National Medical Products Administration) approved compounds, which have undergone extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE NMPA-Approved Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.
|
|
84
|
| HY-L075 | Anti-Lung Cancer Compound Library |
Lung cancer is a major global health problem, as it is the leading cause of cancer-related deaths worldwide. Lung cancer is divided into two categories: small cell lung cancer and non-small cell lung cancer (NSCLC). Non-small cell lung cancer accounts for about 85 percent of lung cancers.
As with all cancers, lung cancer may be treated with surgery, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. Targeted therapy is one of the most exciting developments in lung cancer medicine, especially for NSCLC. Extensive genomic characterization of NSCLC has led to the identification of molecular subtypes of NSCLC that are oncogene addicted and exquisitely sensitive to targeted therapies. These include activating mutations in epidermal growth factor receptor (EGFR) and BRAF or echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusions and ROS1 receptor tyrosine kinase fusions. These are important targets for target therapy.
MCE offers a unique collection of 3,061 compounds with identified and potential anti-lung cancer activity. These compounds target lung cancer’s major targets and signaling pathways. MCE anti-lung cancer compound library is a useful tool for anti-lung cancer drugs screening and other related research.
|
|
84
|
| HY-L116 | EMA-Approved Drug Library |
MCE EMA-Approved Drug Library consists of 728 EMA-approved drugs with high pharmacological diversity. All drugs in this library have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE EMA-Approved Drug Library is a useful tool for drug repurposing which could dramatically accelerate drug development.
|
|
84
|
| HY-L039 | Reprogramming Compound Library |
Techniques for reprogramming somatic cells create new opportunities for drug screening, disease modeling, artificial organ development, and cell therapy. The development of reprogramming techniques has grown exponentially since Yamanaka reprogrammed somatic cells to become induced pluripotent stem cells (iPSCs) using four transcription factors, OCT4, SOX2, KLF4, and c-MYC in 2006. Despite the development of efficient reprogramming methods, most methods are inappropriate for clinical applications because they carry the risk of integrating exogenous genetic factors or use oncogenes. Alternative approaches, such as those based on miRNA, non-viral genes, non-integrative vectors, and small molecules, have been studied as possible solutions to the problems. Among these alternatives, small molecules are attractive options for clinical applications. Reprogramming using small molecules is inexpensive and easy to control in a concentration- and time-dependent manner. It offers a high level of cell permeability, ease of synthesis and standardization, and it is appropriate for mass-producing cells.
MCE Reprogramming Compound Library contains a unique collection of 3,231 compounds that act on reprogramming signaling pathways. These compounds are potential stimulators for reprogramming. This library is a useful tool for researching reprogramming and regenerative medicine.
|
|
83
|
| HY-L079 | Anti-Blood Cancer Compound Library |
Blood cancers, also called hematologic cancers, occur when abnormal blood cells start growing out of control, interrupting the function of normal blood cells, which fight off infection and produce new blood cells. Most blood cancers start in the bone marrow, which is where blood is produced. There are three main types of blood cancers: leukemia, lymphoma and myeloma, which afflict millions of children and adults every year, and are often deadly.
Some common blood cancer treatments include stem cell transplantation, chemotherapy, radiation therapy, targeted therapy, immunotherapy or a combination thereof. As we begin to understand the key signaling pathways and molecular drivers of malignant transformation in haematological disorders, new treatment strategies will continue to be developed.
MCE offers a unique collection of 4,333 compounds with identified and potential anti-blood cancer activity. These compounds target blood cancer’s major targets and signaling pathways. MCE anti-blood cancer compound library is a useful tool for anti-blood cancer drugs screening and other related research.
|
|
83
|
| HY-L097 | Animal Disease Model Inducer Library |
Animal disease models are used in a variety of settings in basic research, such as studies on mechanisms of disease progression and evaluation new drugs. Animal models can be broadly classified into five categories: 1) experimental, 2) spontaneous, 3) negative, 4) orphan, 5) genetically engineered. Experimental models, which are induced artificially in the laboratory, are most common. Some small molecular compounds are usually used as inducers for animal models, such as Ceruletide for inflammatory model, Azoxymethane for tumor model. These inducers are useful tool in building animal models.
MCE offers a unique collection of 52 animal model inducers, involving inflammatory model, tumor model, nervous disease model, etc. MCE Animal Disease Model library is a powerful tool for the establishment of animal disease models.
|
|
83
|
| HY-L098 | Drug Metabolite Library |
A drug metabolite is a byproduct of the body breaking down, or “metabolizing” a drug into a different substance. Most drugs undergo chemical alteration by various bodily systems as a way to create compounds that are more easily excreted from the body. Drugs can be metabolized by oxidation, reduction, hydrolysis, hydration, conjugation, condensation, or isomerization. Drug metabolism can produce metabolites with physicochemical and pharmacological properties that differ substantially from those of the parent drug, and consequently have important implications for both drug safety and efficacy.
MCE offers a unique collection of 440 drug metabolites which is a useful tool for drug safety and efficacy study and drug repurposing.
|
|
83
|
| HY-L140 | Withdrawn Drug Compound Library |
Withdrawal or delisting drugs refer to drugs that are recalled or discontinued from the market due to low efficiency, serious side effects, financial and regulatory problems and other reasons. Once the drug is withdrawn from the market, it will cause heavy losses to the original research company that invested a lot of time, finance and other costs to develop the drug.
Adverse drug reaction (ADR) is the main reason for drug withdrawal from the market. ADR refers to the unexpected effects caused by the reasons such as the target-directed interaction during the treatment. However, studying the mechanism of these ADRs may just be a breakthrough in finding new indications. For example, thalidomide, the protagonist of the drug damage event that caused numerous "seal babies" deformed infants, was found to be due to the degradation of a transcription factor - SALL4 after delisting, which made thalidomide have a new clinical application. In 1998, it was approved by FDA for the treatment of leprosy nodular erythema, and in 2006, it was approved for the treatment of multiple myeloma. ADR study of delisted drugs can not only avoid the loss of drug development in advance but also bring hope to new indications.
MCE has sorted out 232 drug compounds withdrawn from the market through FDA, EMA and other authoritative platforms. Each compound has withdrawal records in at least one country/market. It is a useful tool for conducting research on drug side effects or drug toxicity mechanisms and discovering new indications of drugs.
|
|
83
|
| HY-L141 | Off-patent Drug Library |
Drug repurposing (also called drug repositioning, reprofiling, or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, for example, lower risk of failure, less investment, and shorter development timelines. But drug repositioning projects are also subject to several risks, including regulatory and intellectual property issues. So the off-patent drugs are optimal for repositioning because of their immediate availability for clinical studies, with high feasibility and relatively low risk.
MCE carefully prepared a unique collection of 2,921 off-patent drugs, which is a good choice for drug repurposing.
|
|
83
|
| HY-L174 | Macrophage Related Compound Library |
Macrophages are effector cells of the innate immune system, engulfing bacteria and secreting pro-inflammatory and antibacterial mediators. They are an important component of the first line defense against pathogens and tumor cells. In addition, macrophages play an important role in eliminating damaged cells through programmed cell death. Like all immune cells, macrophages originate from pluripotent hematopoietic stem cells in the bone marrow. Macrophages play key functions in many physiological processes beyond homeostasis and innate immunity, including metabolic function, cell debris clearance, tissue repair, and remodeling. In order to fulfill their different functional roles, macrophages can polarize into a series of phenotypes, including classic (pro inflammatory, M1) and alternative (anti-inflammatory, healing promoting, M2) activation states, as well as a wide range of regulatory phenotypes and subtypes. Macrophages exist in all vertebrate tissues and have a dual function in host protection and tissue damage, maintaining a good balance.
MCE designs a unique collection of 276 macrophage related compounds. It is a good tool to be used for research on Inflammation, cancer and other diseases.
|
|
83
|
| HY-L210 | Anti-Rheumatic Arthritis Compound Library |
Rheumatoid Arthritis (RA) is a autoimmune disease characterized by persistent joint inflammation. The pathology of RA includes immune cell infiltration, synovial lining proliferation, pannus formation, and the destruction of joint cartilage and bone, which is highly disabling. Due to long-term chronic inflammation, RA not only severely affects the quality of life of patients but can also damage multiple organs, leading to lung diseases, cardiovascular diseases, and malignant tumors. The pathogenesis of RA is complex, involving genetic, environmental, and immune factors. With the advancement of high-throughput screening technology, screening for compounds targeting JAK, CCR, MEK, MMP targets may contribute to the development of more effective drugs against Rheumatoid Arthritis (RA).
MCE has collected 2,023 small molecule compounds with definite or potential anti-rheumatoid arthritis activity. This library is of significant value for researching the anti-RA drugs.
|
|
83
|
| HY-L213 | Anti-Cancer Approved Drug Library |
The anti-cancer drug library meticulously collects all drugs approved by FDA and other major national drug regulatory authorities for cancer treatment. These drugs cover a variety of cancer types, including but not limited to lung cancer, breast cancer, colorectal cancer, leukemia, and other common cancers. The library includes a wide range of drugs, from classic chemotherapeutic agents to cutting-edge targeted therapies and immunotherapies. It contains various types of drug compounds with different mechanisms of action. There are cytotoxic drugs that directly kill cancer cells, as well as drugs that work by modulating the tumor microenvironment, inhibiting tumor angiogenesis, and activating the immune system. This diversity provides researchers with a broad range of perspectives and options for intervention strategies.
This library can be used for basic research on cancer treatment, exploring new targets and new mechanisms of drug action; Conducting drug reuse research to look for potential therapeutic effects of existing drugs on other cancer types or diseases; Or conducting research into combination drugs to optimize cancer treatment.
MCE has collected 265 small-molecule compounds with cancer indications, which are good tools for drug repurposing.
|
|
83
|
| HY-L218 | Animal Drug Library |
Animal drug (also veterinary drug) refers to a drug intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in animals. Animal Drugs @ FDA is a searchable online database that includes most FDA-approved and conditionally approved animal drugs. The major classes of veterinary drugs include antibiotics, anthelmintics, coccidiostats, nonsteroidal anti-inflammatory drugs, sedatives, corticosteroids, beta-agonists, and anabolic hormones.
MCE has collected 166 FDA-approved veterinary drug compounds for use in scientific research.
|
|
83
|
| HY-L948 | PD-1/PD-L1 Lead-like Library |
PD-1/PD-L1 are key immune checkpoint targets that suppress T-cell-mediated anti-tumor immunity, representing a major focus in cancer immunotherapy. While antibody drugs dominate the clinic, they are limited by administration challenges and immune-related side effects. Small-molecule PD-1/PD-L1 inhibitors, with oral availability, good tissue penetration and low cost, have emerged as a promising next-generation strategy.
A PD-1/PD-L1 lead-like library was built via a five-step virtual screening process. After collecting 8,947 inhibitors from BindingDB and PubChem and filtering by activity and duplicates, AI similarity screening was performed using GeminiMol. Key pharmacophores were extracted from the PPI interface of co-crystal structures, and molecular was screened via a pharmacophore model, effectively enhancing target activity.
Containing 10,000 structurally diverse and drug-like molecules well-matched to the PD-L1 pocket, the library supports virtual docking, high-throughput screening and hit discovery, enabling efficient and rapid development of small-molecule immunotherapies.
|
|
83
|
| HY-16711 | SB225002 |
|
66
|
|
| HY-15251 | Reparixin |
Metabolic or Endocrine Disease
Gastric Cancer
Pancreatic Cancer
Digestive System Inflammation
Rheumatoid Arthritis
|
65
|
|
| HY-15319 | AMG 487 |
AMG 487 is an orally active and selective antagonist of CXC chemokine receptor 3 (CXCR3) which inhibits the binding of CXCL10 and CXCL11 to CXCR3 with IC50s of 8.0 and 8.2 nM, respectively.
|
Cancer
Metabolic or Endocrine Disease
Digestive System Disease
Digestive System Inflammation
Rheumatoid Arthritis
|
40
|
| HY-P9902 | Pembrolizumab |
Pembrolizumab (MK-3475) is a humanized IgG4 antibody inhibiting the programmed cell death 1 (PD-1) receptor, used in cancer immunotherapy.
Species: Human |
Non-Small Cell Lung Cancer
Lung Adenocarcinoma
HER-2 Positive Breast Cancer
Triple-Negative Breast Cancer
Metastatic Breast Cancer
|
37
|
| HY-10198 | Navarixin |
Metabolic or Endocrine Disease
Prostate Cancer
Gastric Cancer
Digestive System Inflammation
SARS-CoV-2 Infection
Rheumatoid Arthritis
|
32
|
|
| HY-13848 | Rugocrixan |
|
26
|
|
| HY-N7131 | Coumarin 6 |
Coumarin 6, a fluorescent dye, is used as a fluorescent probe in a microparticle drug delivery system to conduct in vivo tracking, cell uptake, and transport mechanism studies of drug delivery systems (λexc=450 nm, λem=505 nm).
|
|
24
|
| HY-16438 | RRx-001 |
RRx-001, a hypoxia-selective epigenetic agent and studied as a radio- and chem-sensitizer, triggers apoptosis and overcomes agent resistance in myeloma. RRx-001 exhibits potent anti-tumor activity with minimal toxicity. RRx-001 is a dual small molecule checkpoint inhibitor by downregulating CD47 and SIRP-α. RRx-001 is a potent inhibitor of G6PD and shows potent antimalarial activity.
|
Digestive System Disease
Lung Cancer
Leukemia/Lymphoma/Myeloma
Parasitic Infection
Digestive System Inflammation
SARS-CoV-2 Infection
|
22
|
| HY-143218 | TPE-MI |
TPE-MI (Tetraphenylethene maleimide) is a thiol probe for measuring unfolded protein load and proteostasis in cells (the excitation wavelength is 350 nm and the emission wavelength is 470 nm). TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasites Plasmodium falciparum .
|
|
18
|
| HY-13406 | TAK-779 |
Cancer
Metabolic or Endocrine Disease
Digestive System Disease
Viral Infection
Digestive System Inflammation
Lung Fibrosis
Rheumatoid Arthritis
|
13
|
|
| HY-19855 | AZD-5069 |
AZD-5069 is a potent CXCR2 chemokine receptor antagonist, used for caner treatment.
|
Metabolic or Endocrine Disease
Prostate Cancer
Gastric Cancer
Pancreatic Cancer
Digestive System Inflammation
Rheumatoid Arthritis
|
11
|
| HY-100806 | Kynurenic acid |
Kynurenic acid, an endogenous tryptophan metabolite, is a broad-spectrum antagonist targeting NMDA, glutamate, α7 nicotinic acetylcholine receptor. Kynurenic acid is also an agonist of GPR35/CXCR8.
|
Cancer
Metabolic or Endocrine Disease
Digestive System Disease
Depression
Digestive System Inflammation
Alzheimer's Disease
Parkinson's Disease
|
11
|
| HY-109506 | DPPC |
DPPC (129Y83) is a phosphoglyceride that can be used to prepare lipid monolayers, bilayers, and liposomes. DPPC is the main lipid component of pulmonary surfactant. Dppc-liposome can be effectively used as a delivery vector to induce an immune response against GSL antigen in mice.
|
|
10
|
| HY-107780A | Cyclic-di-GMP sodium |
Cyclic-di-GMP sodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP sodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP sodium can be used in cancer research.
Source: bacterial species |
|
9
|
| HY-107780 | Cyclic-di-GMP |
Cyclic-di-GMP is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP can be used in cancer research.
Source: bacterial species |
|
9
|
| HY-107780B | Cyclic-di-GMP diammonium |
Cyclic-di-GMP diammonium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP diammonium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP diammonium can be used in cancer research.
|
|
9
|
| HY-110382 | Cyclic-di-GMP disodium |
Cyclic-di-GMP disodium is a STING agonist and a bacterial second messenger that coordinates different aspects of bacterial growth and behavior, including motility, virulence, biofilm formation, and cell cycle progression. Cyclic-di-GMP disodium has anti-cancer cell proliferation activity and also induces elevated CD4 receptor expression and cell cycle arrest. Cyclic-di-GMP disodium can be used in cancer research.
|
|
9
|
| HY-N7032 | Uridine 5′-diphosphoglucose disodium |
Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
|
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
9
|
| HY-P99032 | Monalizumab |
Monalizumab (IPH2201) is an immune checkpoint inhibitor targeting Natural Killer Group 2A (NKG2A). Monalizumab, a humanized anti-NKG2A blocking mAb, increases IFN-γ production, thereby promoting NK cell effector functions. Monalizumab can be used for the research of head and neck squamous cell carcinoma (HNSCC).
Species: Human |
|
7
|
| HY-N0762 | Isobavachin |
Isobavachin is an orally active, blood-brain barrier-penetrating prenylated flavonoid present in Psoralea corylifolia. Isobavachin inhibits human CYP2B6, CYP2C9, CYP2C19, UGT1A1, UGT1A9, and UGT2B7. Isobavachin suppresses MAPK activation, NF-κB nuclear translocation, overexpression of iNOS/COX-2, FcεRI-mediated signaling pathways, and RANKL-induced osteoclastogenesis. Isobavachin induces autophagy, cytotoxicity, neuronal differentiation, and NRF2 activation; it alleviates oxidative damage, inflammatory responses, apoptosis, iron accumulation, mitochondrial biogenesis, and mast cell degranulation. Isobavachin is applicable to research related to liver injury, inflammatory diseases, osteoporosis, liver cancer, prostate cancer, glioma, periodontitis-induced bone loss, and Alzheimer's disease.
|
Cytochrome P450
UGT
p38 MAPK
NF-κB
NO Synthase
COX
Fc Receptor (FcR)
RANKL/RANK
Keap1-Nrf2
Reactive Oxygen Species (ROS)
Apoptosis
Autophagy
Prostate Cancer
Liver Cancer
Glioma
Allergy
Acute Myeloid Leukemia
Alzheimer's Disease
Antioxidant Agent
Osteoporosis
Liver Injury
Osteoarthritis
Rheumatoid Arthritis
|
6
|
| HY-P99188 | Carlumab |
Carlumab (CNTO 888) is a human anti-CCL2 (chemokine ligand 2) monoclonal antibody. Carlumab binds and neutralises profibrotic activities of human CCL2. Carlumab inhibits tumor growth by reducing macrophage infiltration and decreasing tumor microvascular density. Carlumab can be used for the research of cancer, suah as prostate cancer.
Species: Human |
|
5
|
| HY-P99029 | Magrolimab |
|
5
|
|
| HY-P99979 | Rat IgG1 kappa, Isotype Control |
Rat IgG1 kappa, Isotype Control, a rat monoclonal antibody, is an isotype control for Rat IgG1κ antibody.
|
|
3
|
| HY-P99037 | Nipocalimab |
Nipocalimab (M281) is a fully humanized, recombinant, and non-glycosylated IgG1 monoclonal antibody. Nipocalimab can bind to the IgG-binding site of FcRn with high affinity and inhibit the transplacental transfer of IgG. Nipocalimab can be used in the research of fetal and neonatal hemolytic disease, myasthenia gravis, and various IgG-mediated autoimmune diseases.
Species: Human |
|
3
|
| HY-108910 | Chymotrypsin |
Chymotrypsin (EC 3.4.21.1; Chymotrypsin A) is an orally effective inhibitor targeting molecules such as TLR4, NF-κB, MMP-1, TNF-α, IL-1β, and IL-6. Chymotrypsin downregulates the TLR4/NF-κB signaling pathway, inhibiting the release of inflammatory factors, reducing cell infiltration and tissue damage. It also reduces the expression of tumor cell adhesion molecules (such as CD44 and CD54) and can be specifically detected by fluorescent probes (such as NBD-3). Chymotrypsin has anti-inflammatory, hepatoprotective, joint damage-reducing, liver protection against lipotoxicity, and anti-tumor metastasis functions. It can be used in research on diseases such as rheumatoid arthritis, non-alcoholic fatty liver disease, and melanoma metastasis. Chymotrypsin can be used in studies of inflammation, edema, and expectoration.
|
Breast Cancer
Digestive System Inflammation
Gastric Disease
Metastatic Melanoma
Pharyngitis
Rheumatoid Arthritis
|
3
|
| HY-K0225 | Carboxyl Magnetic Beads (200 nm, 10 mg/mL) |
MCE Carboxyl Magnetic beads (200 nm, 10 mg/mL) are characterized by superparamagnetism, fast magnetic response, abundant carboxyl functional groups, monodispersity, and submicron scale particle size. Biological ligands (proteins, peptides, oligonucleotides, drug molecules, etc.) can be covalently coupled to the surface of microspheres under the action of special chemical reagents (such as EDC). |
|
3
|
| HY-K1099 | Endotoxin Detection Kit (Recombinant Factor C) |
MCE Endotoxin Detection Kit (Recombinant Factor C) is suitable for the detection of endotoxins in therapeutic injectable drugs for human use (such as chemical drugs, antibiotics, and biologics), as well as in medical devices including dialysis fluids and implantable devices. It can be applied throughout raw material screening, process development, manufacturing, and commercialization stages. |
|
3
|
| HY-P2300A | Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA |
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA, a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used in the research of tumors.
|
|
2
|
| HY-N0508 | Rosin |
Rosin is a natural oleoresin found in coniferous trees of the genus Pinus, such as Pinus massoniana. Rosin exhibits cholesterol-lowering, anti-gastric ulcer, anti-tumor, blood glucose-lowering, and anti-macrocyte aggregation activities. Rosin inhibits TPA (HY-18739)-induced EBV-EA activation and suppresses papilloma formation in a two-stage mouse skin carcinogenesis model. WBR, a processed product of Rosin, inhibits the IL-23/IL-17 inflammatory axis and reduces Th1 and Th17 cell infiltration. Rosin is used in research on psoriasis and skin cancer.
|
|
2
|
| HY-P4846 | Ac-Pro-Gly-Pro-OH |
Ac-Pro-Gly-Pro-OH is an endogenous degradation product of extracellular collagen and acts as a CXCR2 agonist. Ac-Pro-Gly-Pro-OH exerts bactericidal activity by generating hydrogen peroxide, inhibits pulmonary inflammation, and reduces immune cell apoptosis (apoptosis). Ac-Pro-Gly-Pro-OH promotes the production of IFN-γ and inhibits the production of TNF-α and IL-6 in leukocytes. Ac-Pro-Gly-Pro-OH increases the survival rate of mice in sepsis models, enhances the bactericidal activity of neutrophils, acts as a neutrophil chemoattractant, induces neutrophil polarization, and regulates inflammatory and repair processes. Ac-Pro-Gly-Pro-OH induces chronic inflammation and tissue remodeling through sustained action. Ac-Pro-Gly-Pro-OH is released via alkaline hydrolysis of corneal proteins in alkali-injured eyes, thereby driving the early infiltration of neutrophils into the cornea. Ac-Pro-Gly-Pro-OH is applicable to research related to sepsis, chronic obstructive pulmonary disease, cystic fibrosis, bronchiolitis obliterans syndrome, severe asthma, idiopathic pulmonary fibrosis, and corneal ulcer.
|
|
2
|
| HY-P990131 | Anti-Mouse CD47/IAP Antibody (MIAP301) |
Anti-Mouse CD47/IAP Antibody (MIAP301) is an anti-mouse CD47/IAP IgG2a monoclonal antibody. Anti-Mouse CD47/IAP Antibody (MIAP301) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse CD47/IAP Antibody (MIAP301) can increase the infiltration of immune cells. Anti-Mouse CD47/IAP Antibody (MIAP301) restores the phagocytic function of myeloid cells and alleviate B cell inhibition. Anti-Mouse CD47/IAP Antibody (MIAP301) may interfere with wound healing. Anti-Mouse CD47/IAP Antibody (MIAP301) can be used for researches on cancer, inflammation and infection conditions such as melanoma, intestinal mucosal repair and sepsis.
Species: Mouse |
|
2
|
| HY-P990212 | Anti-Mouse IL-6 Antibody (MP5-20F3) |
Anti-Mouse IL-6 Antibody (MP5-20F3) is an anti-mouse IL-6 IgG1 monoclonal antibody. Anti-Mouse IL-6 Antibody (MP5-20F3) reshapes the tumor microenvironment by blocking IL-6. Anti-Mouse IL-6 Antibody (MP5-20F3) can inhibit the STAT3 pathway and enhance T cell infiltration. Anti-Mouse IL-6 Antibody (MP5-20F3) can be used for researches on inflammation and infection conditions such as malignant pleural effusion (MPE).
Species: Mouse |
|
2
|
| HY-P10102 | Kp7-6 |
Kp7-6 is a Fas mimetic peptide and also a Fas/FasL antagonist. Kp7-6 specifically binds to Fas and FasL, disrupts receptor complexes, and blocks downstream apoptosis signaling pathways. Kp7-6 inhibits the phosphorylation of ERK1-2, induces the phosphorylation of IκBα, and activates NF-κB. Kp7-6 inhibits the activation of caspase-8, caspase-3 and JNK, and suppresses human amylin-induced β-cell apoptosis. Kp7-6 inhibits FasL-induced lymphoid cytotoxicity and apoptosis. Kp7-6 reduces local tumor FasL expression, increases CD8+Fas+ T cell infiltration, and decreases tumor volume in pancreatic neuroendocrine tumor models. Kp7-6 prevents concanavalin A-induced liver injury in mice. Kp7-6 is applicable to research related to type 2 diabetes, concanavalin A-induced hepatitis and pancreatic neuroendocrine tumors.
|
|
2
|
| HY-119109 | Laminaran |
Laminaran is an β-1-3-glucan and a typical ligand for Dectin-1 from Eisenia Bicyclis, has potent immunomodulating, radioprotective, and anticancer activities. Laminaran is made up of β (1→3)-glucan with β (1→6)-branches and can be catalyzed by enzymes such as laminarinase (EC 3.2.1.6) that breaks the β (1→3) bonds. Laminaran is a promising immune stimulatory molecule for use in cancer immunotherapy.
Source: Eisenia Bicyclis |
|
2
|
| HY-P2300 | Cyclo(Arg-Gly-Asp-D-Phe-Cys) |
Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC), a cyclic RGD peptide which has high affinity to αvβ3, can disrupt cell integrin interactions. Cyclo(Arg-Gly-Asp-D-Phe-Cys) inhibits pluripotent marker expression in embryonic stem cells (ESCs) and the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) can be used in the research of tumors.
|
|
2
|
| HY-158226 | Elastin Methacrylated |
Elastin Methacrylated (ElaMA) elastin recruits and modulates innate immune cells and accelerates angiogenesis at the wound site, thereby improving wound regeneration. Elastin Methacrylated attracts large numbers of neutrophils and primarily M2 macrophages to the wound and induces their penetration into the hydrogel. Elastin Methacrylated has excellent immunomodulatory effects, leading to superior angiogenesis, collagen deposition and dermal regeneration. Elastin Methacrylated needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
Application: cell culture, biological 3D printing, tissue engineering, etc. |
|
1
|
| HY-N5084 | Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside |
Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside is a TRPV1 antagonist and HDAC7 inhibitor. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside blocks TRPV1-mediated calcium influx, suppresses phosphorylation of p65, IκBα, p38, JNK, and ERK1/2, inhibiting NF-κB and MAPK signaling cascades. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside reduces production and gene expression of pro-inflammatory cytokines IL-1β, IL-6, and TNF-α. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside exhibits potent analgesic activity, elevates thermal pain threshold and mechanical pain threshold in murine models. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside restores CD8+ T cell infiltration into bladder cancer tumors and improves bladder cancer immunotherapy efficacy. Pinocembrin 7-O-[3''-O-galloyl-4'',6''-hexahydroxydiphenoyl]-β-D-glucoside can be used for the researches of painand bladder cancer.
|
|
1
|
| HY-P99142 | Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) |
Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) is an anti-mouse Ly-6G/Ly-6C IgG2b monoclonal antibody. Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) can deplete neutrophils and monocytes. Anti-Mouse Ly-6G/Ly-6C Antibody (RB6-8C5) can be used for research on immunology.
Species: Mouse |
|
1
|
| HY-P99026 | Lemzoparlimab |
|
1
|
|
| HY-P990255 | Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) |
Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) is an anti-mouse CXCL9/MIG IgG monoclonal antibody. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can reduce tumor infiltration of CD8+ cytotoxic T cells (CTLs). Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can prolong the survival of transplanted hearts. Anti-Mouse CXCL9/MIG Antibody (MIG-2F5.5) can be used for researches on immunology and cancer such as prostate cancer.
Species: Mouse |
|
1
|
| HY-128754 | Monoolein |
Monoolein is a biocompatible lipid molecule that can be used as a carrier for bone repair. Monoolein exhibits anti-inflammatory activity by inhibiting the immune response induced by LPS (HY-D1056). It exerts its anti-inflammatory effects by reducing the production of immune response factors such as IL-12 p40, IL-6, and TNF-α, and inhibiting the generation of NO. Monoolein can be used in drug delivery and research in the field of inflammatory diseases .
|
|
1
|
| HY-P99533 | Urabrelimab |
Urabrelimab (SRF231) is a fully human anti-CD47 monoclonal antibody that blocks the CD47-SIRP interaction.
Species: Human |
|
1
|
| HY-P10128 | GE11 |
GE11 is a active peptide and combines with colloidal drug delivery systems as smart carriers for antitumor drugs and can be used for cancer study.
|
|
1
|
| HY-125527 | Resolvin D1 |
Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α–mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages.
|
|
1
|
| HY-P99300 | Ligelizumab |
Ligelizumab (QGE 031) is a humanized high-affinity anti-immunoglobulin IgE monoclonal antibody. Ligelizumab selectively inhibits the binding of IgE to the high-affinity receptor FcεRI, while the inhibitory effect on the low-affinity receptor CD23 is weak. Ligelizumab can inhibit the activation of effector cells such as mast cells and Basophil, while reducing the production of IgE by B cells, and restoring the IFN-α production and regulatory T cell (Treg) induction function of plasmacytoid dendritic cells (pDC). Ligelizumab can be used in the study of allergic diseases (such as chronic spontaneous urticaria, allergic asthma).
Species: Human |
|
1
|
| HY-P2529 | Penetratin |
Penetratin is a cell-penetrating peptides derived from a nonviral protein. Penetratin can powerfully enhance drug absorption. Penetratin can be used for drug delivery research in the treatment of various diseases.
|
|
1
|
| HY-125474 | Carrageenan |
Carrageenan is an antiviral and anticancer agent. Carrageenan inhibits herpes simplex virus (HSV), HIV, and hepatitis A virus (HAV) by directly binding to the viral capsid to block the attachment of viruses such as HPV to HSPG factors on the cell surface. Carrageenan delays and arrests cell cycle progression, exhibits cytotoxicity against HeLa cancer cells, and can be applied to studies related to cervical cancer, genital warts, hepatitis A, and other conditions. Carrageenan also induces acute non-immune inflammation, triggers a three-phase inflammatory response involving the release of multiple proinflammatory mediators, and causes persistent edema, hyperalgesia, and neutrophil recruitment in mice.
|
|
1
|
| HY-P99014 | Cusatuzumab |
Cusatuzumab (ARGX-110) is a selective competitive blocker targeting CD70 (with an equilibrium dissociation constant of 17 pM for binding to human CD70). Cusatuzumab also possesses enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. It is a humanized IgG1 monoclonal antibody, artificially synthesized through humanization and genetic engineering modifications (CH2 region mutation to enhance effector function). Cusatuzumab has a dual mechanism of action: firstly, it competitively blocks the interaction between CD70 and CD27, inhibiting the CD27-NF-κB signaling pathway, reducing regulatory T cell (Treg) activation and tumor cell proliferation; secondly, by enhancing binding to FcγRIIIa, it mediates ADCC and antibody-dependent cellular phagocytosis (ADCP), directly lysing CD70-positive tumor cells. Cusatuzumab can efficiently eliminate leukemia stem cells (LSCs), induce tumor cell differentiation and apoptosis, restore immune surveillance, and target CD70-positive tumors. Cusatuzumab is used in the study of acute myeloid leukemia (AML).
Species: Human |
|
1
|
| HY-P3161 | Lactoferrin from Bovine milk |
Lactoferrin from Bovine milk is a substance released by neutrophils. Lactoferrin from Bovine milk is an orally active multifunctional iron binding glycoprotein. Lactoferrin from Bovine milk prevents cell adhesion, growth and spreading of cell colonies. Lactoferrin from Bovine milk also has antiviral activity and inhibits microbial and viral adhesion and entry into host cells. Besides, Lactoferrin from Bovine milk has anti-inflammatory, immunomodulatory, and anti-cancer activities.
|
|
1
|
| HY-P72507 | MMP-8 Protein, Human (HEK293, His) |
MMP-8, also known as matrix metalloproteinase-8 or collagenase-2, is recognized for its enzymatic abilities, particularly its ability to break down fibrillar types I, II, and III collagen. This enzymatic activity suggests that MMP-8 plays an important role in the remodeling and turnover of collagen-rich tissues such as connective tissue, cartilage, and bone. MMP-8 Protein, Human (HEK293, His) is the recombinant human-derived MMP-8 protein, expressed by HEK293 , with C-10*His labeled tag.
Species: Human; Source: HEK293 |
|
1
|
| HY-P73335 | p38 alpha/MAPK14 Protein, Human (Active, sf9, His) |
The p38 α/MAPK14 protein is an important serine/threonine kinase in the MAP kinase pathway. It can respond to stimuli such as cytokines or stress and directly activate transcription factors. In this cascade, p38 MAPK each phosphorylates approximately 200 to 300 substrates, including the downstream kinases RPS6KA5/MSK1 and RPS6KA4/MSK2, which are critical for immediate early gene induction. p38 alpha/MAPK14 Protein, Human (Activated, sf9, His) is the recombinant human-derived p38 alpha/MAPK14 protein, expressed by Sf9 insect cells , with N-His labeled tag.
Species: Human; Source: Sf9 insect cells |
|
1
|
| HY-P70052 | CXADR Protein, Mouse (HEK293, Fc) |
CXADR protein is a key component of the epithelial apical junction complex, which maintains the integrity of tight junctions and enables leukocyte migration through adhesive interactions with JAML. This interaction activates γ-δ T cells and promotes tissue repair through cell signaling involving PI3 kinase and MAP kinase. CXADR Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived CXADR protein, expressed by HEK293 , with C-hFc labeled tag.
Species: Mouse; Source: HEK293 |
|
1
|
| HY-P86073 | Neutrophil Elastase Antibody (YA5765) |
|
1
|
|
| HY-K0350 | Mouse Neutrophil Negative Selection Kit |
MCE Mouse Neutrophil Negative Selection Kit can isolate neutrophils from single-cell suspensions of mouse bone marrow or other tissue samples. |
|
1
|
| HY-K2016 | Protein Transfection Reagent |
MCE Protein Transfection Reagent is a cationic lipid mixture for complexation with proteins, peptides, antibodies and other biologically active molecules to allow their direct intracellular delivery. |
|
1
|
| HY-14648S2 | Dexamethasone-d4 |
Dexamethasone-d4 is deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
|
Exosomes
Isotope-Labeled Compounds
Glucocorticoid Receptor
SARS-CoV
Autophagy
Complement System
Mitophagy
Bacterial
Antibiotic
|
/
|
| HY-W745090 | Isomaltulose monohydrate |
Isomaltulose monohydrate is a fMLP inhibitor and also inhibits Src kinase, ERK1/2, p38 and AKT phosphorylation signals in immune regulation. Isomaltulose monohydrate can interfere with the interaction between the βγ subunit of the fMLP receptor Gi protein and its downstream molecules, thereby inhibiting fMLP-induced respiratory burst. Isomaltulose monohydrate inhibits fMLP (0.1 μM)-induced superoxide anion production (IC50: 1.98 μM) , cathepsin G release (IC< sub>50: 2.76 μM) and chemotaxis. Isomaltulose monohydrate can improve excessive activation of neutrophils and reduce inflammation or tissue damage. A series of derivatives of Isomaltulose monohydrate are found to have inhibitory effects on FSGS-related TRPC6 functional mutants.
|
|
/
|
| HY-166975 | Polysarcosine 100 |
Polysarcosine 100 (pSar 100) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 100 can be used in drug delivery research.
|
|
/
|
| HY-12292G | IM-12 (GMP) |
IM-12 GMP is IM-12 (HY-12292) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. IM-12 is an orally active anti-inflammatory agent that targets and inhibits the NF-κB and STAT3 signaling pathways. IM-12 activates the Wnt signaling pathway and promotes the nuclear translocation of β-catenin by inhibiting GSK3β, while also blocking the tyrosine kinase activity of p210BCR/ABL. IM-12 reduces the levels of IL-6, IL-17, NO, prostaglandin E2, iNOS and COX-2, and induces ER stress, Ca2+ release, autophagy and apoptosis. IM-12 is heat-sensitive and does not induce autophagy in IM-resistant p210BCR/ABLT315I mutant cells. IM-12 is also a component of the 5iLA medium used for naive pluripotent stem cell research. IM-12 has been applied in studies related to carrageenan (HY-125474)-induced hind paw edema, TNBS-induced colitis, and acute and chronic myeloid leukemia.
|
|
/
|
| HY-N0559A | (6-Rac)-Kirenol |
(6-Rac)-Kirenol is an ent-pimarane-type diterpenoid. (6-Rac)-Kirenol inhibits the production of superoxide anions in activated human neutrophils. (6-Rac)-Kirenol inhibits the release of elastase from activated human neutrophils.
|
|
/
|
| HY-P3648 | Ala-Ala-Pro-Val-chloromethylketone |
Ala-Ala-Pro-Val-chloromethylketone is an irreversible human neutrophil elastase (NE) inhibitor for use in the study of chronic inflammatory airway diseases.
|
|
/
|
| HY-W004260S | Arachidic acid-d2 |
Arachidic acid-d2 is the deuterium labeled Arachidic acid (HY-W004260). Arachidic acid (Eicosanoic acid) is a long-chain saturated fatty acid. Arachidic acid can be found in the human organism from the plasma phospholipid, fish, cannabis and other plant oils. Arachidic acid conjugated with Chitosan oligosaccharide (HY-112108) can be used for anti-cancer drug delivery research.
|
|
/
|
| HY-W700452 | Y-27632-d4 hydrochloride hydrate |
Y-27632-d4 hydrochloride hydrate is the deuterium labeled Y-27632 hydrochloride hydrate (HY-10071A). Y-27632 hydrochloride hydrate is an orally active, ATP-competitive inhibitor of ROCK-I and ROCK-II, with Kis of 220 and 300 nM, respectively. Y-27632 hydrochloride hydrate attenuates Doxorubicin-induced apoptosis of human cardiac stem cells. Y-27632 hydrochloride hydrate also suppresses dissociation-induced apoptosis of murine prostate stem/progenitor cells. Y-27632 hydrochloride hydrate primes human induced pluripotent stem cells (hIPSCs) to selectively differentiate towards mesendodermal lineage via epithelial-mesenchymal transition-like modulation.
|
|
/
|
| HY-70037S | Cinacalcet-d3 |
Cinacalcet-d3 is the deuterium labeled Cinacalcet. Cinacalcet (AMG 073) is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease treatment.
|
|
/
|
| HY-NP216 | PA-IIL |
PA-IIL (LecB) is a lectin produced by Pseudomonas aeruginosa. PA-IIL binds to glycosylated β1-integrin, fucose-containing glycosphingolipids, fucosylated/mannosylated neutrophil glycoconjugates, and pre-formed neutrophil extracellular traps. PA-IIL disrupts host defenses: it creates favorable conditions for Pseudomonas aeruginosa infection and dissemination by modulating the bactericidal activity of neutrophils, impairing the trafficking and recruitment of immune cells, and compromising the repair capacity of epithelial barriers. PA-IIL can be used in studies related to Pseudomonas aeruginosa infection.
|
|
/
|
| HY-W015026S | Isobutylparaben-d4 |
Isobutylparaben-d4 is the deuterium labeled Isobutylparaben. Isobutylparaben (Isobutyl 4-hydroxybenzoate) is the agonist for PXR, CAR and PPAR. Isobutylparaben has a broad-spectrum antimicrobial activity and widely used in personal care products and cosmetics.
|
|
/
|
| HY-W590537 | LC10 |
LC10 is a cholesterol derivative that can be used in drug delivery studies.
|
|
/
|
| HY-B0349S | Meclizine-d8 |
Meclizine-d8 is a deuterium labeled Meclizine. Meclizine is a histamine H1 receptor antagonist and has the potential to treat nausea and motion sickness. Meclizine is an agonist ligand for mouse constitutive androstane receptor (CAR) and an inverse agonist for Human CAR.
|
|
/
|
| HY-W004260S5 | Arachidic acid-d4-1 |
Arachidic acid-d4-1 is the deuterium labeled Arachidic acid (HY-W004260). Arachidic acid (Eicosanoic acid) is a long-chain saturated fatty acid. Arachidic acid can be found in the human organism from the plasma phospholipid, fish, cannabis and other plant oils. Arachidic acid conjugated with Chitosan oligosaccharide (HY-112108) can be used for anti-cancer drug delivery research.
|
|
/
|
| HY-P10560 | M918 |
M918 is a cell-penetrating peptide. M918 is internalized by cells through endocytosis and can effectively penetrate a variety of cells in a non-toxic manner. M918 can be used in gene therapy and drug delivery system research.
|
|
/
|
| HY-P992344 | DNP002 |
DNP002 is a humanized IgG1 monoclonal antibody targeting tumor-associated CEACAM6. DNP002 binds to CEACAM1, CEACAM5 and CEACAM6, and exhibits antibody-dependent cellular cytotoxicity against tumor cells overexpressing these targets. DNP002 binds to CEACAM6 on the surface of tumor-associated neutrophils (including MDSCs) to reverse the immunosuppressive effect in the tumor microenvironment. DNP002 shows anti-tumor activity in advanced solid tumors. DNP002 can be used for the research of advanced solid tumors. The recommended isotype control is human IgG1 kappa (HY-P99001).
Species: Human |
|
/
|
| HY-DY1024 | TPE-MI (solution) |
TPE-MI (Tetraphenylethene maleimide) (solution) is a thiol probe for measuring unfolded protein load and proteostasis in cells (the excitation wavelength is 350 nm and the emission wavelength is 470 nm). TPE-MI can report imbalances in proteostasis in induced pluripotent stem cell models of Huntington disease, as well as cells transfected with mutant Huntington exon 1 before the formation of visible aggregates. TPE-MI also detects protein damage following dihydroartemisinin research of the malaria parasitesPlasmodium falciparum .
Solvent and concentration: DMSO: 10 mM |
|
/
|
| HY-P992178 | ALLO-647 |
ALLO-647 is a human monoclonal antibody targeting CD52. ALLO-647 transiently and selectively depletes host lymphocytes to promote the proliferation of allogeneic CAR T-cell following infusion. ALLO-647 can be used for the research of B-cell lymphoma and follicular lymphoma.
Species: Human |
|
/
|
| HY-158217B | GelMA, 90% methacrylation, Green Fluorescent |
Green Fluorescent Gelatin Methacryloyl (Green Fluorescent GelMA) is methacryloyl gelatin (GelMA) with green fluorescence, which is obtained by "grafting" fluorescent molecules on GelMA. Green Fluorescent Gelatin Methacryloyl acts as a scaffold and can be used to engineer tissue analogs from the vasculature to cartilage and bone, allowing cells to proliferate and spread. GelMA, 90% methacrylation, Green Fluorescent needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
Application: cell culture, biological 3D printing, tissue engineering, etc. |
|
/
|
| HY-109541S3 | Colfosceril miristate-d13 |
Colfosceril miristate-d13 (DMPC-d13) is deuterium labeled Colfosceril miristate. Colfosceril miristate a synthetic phospholipid used in liposomes. Colfosceril miristate is used to study lipid monolayers, bilayers and drug delivery.
|
|
/
|
| HY-109541S | Colfosceril miristate-d58 |
Colfosceril miristate-d58 (DMPC-d58) is deuterium labeled Colfosceril miristate. Colfosceril miristate a synthetic phospholipid used in liposomes. Colfosceril miristate is used to study lipid monolayers, bilayers and drug delivery.
|
|
/
|
| HY-B1380A | Carisoprodol/BSA |
Carisoprodol/BSA (CAR/BSA) is an antigen-adjuvant conjugate conjugate of Carisoprodol and BSA. By conjugating the antigen with a protein adjuvant, the production of antigen-specific antibodies in vaccine models can be enhanced. The conjugate does not affect protein folding or disrupt major epitopes, and can enhance cross-presentation and the production of antigen-specific T cells.
|
|
/
|
| HY-P99772 | Onfekafusp alfa |
|
/
|
|
| HY-166996 | Bis(N-2-ethoxyethyl 2-hexyldecanoate)amine |
Bis(N-2-ethoxyethyl 2-hexyldecanoate)amine is a PEG lipid that can improve the delivery efficiency and tissue specificity of poorly soluble drugs. Bis(N-2-ethoxyethyl 2-hexyldecanoate)amine can be used in drug delivery research.
|
|
/
|
| HY-D1598 | Sulfo-CY3 tetrazine potassium |
Sulfo-CY3 tetrazine potassium is a sulfo-Cyanine3 derivative that contains methyltetrazine moiety (Ex=548 nm, Em=563 nm). Sulfo-CY3 tetrazine potassium can be used for the labeling of metabolically engineered cell-surface glycoconjugates. Sulfo-CY3 tetrazine (potassium) is a click chemistry reagent, it contains a Tetrazine group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing TCO groups.
|
|
/
|
| HY-142985 | Oleyl Mesylate |
Oleyl Mesylate is a derivative of Oleyl Alcohol. Oleyl Alcohol has been incorporated into various formulations for drug delivery.
|
|
/
|
| HY-N3566 | Cepharadione A |
Cepharadione A can be isolated from the roots of Piper betle Linn. Cepharadione A inhibits FMLP/CB induced elastase release by human neutrophils.
|
|
/
|
| HY-P11928 | TC6-D3 |
TC6-D3 is a proteolysis-resistant peptide and also a CC chemokine receptor 7 (CCR7) inhibitor, with a Kd value of 403 nM against mouse targets. TC6-D3 blocks the interaction between CCR7 and its ligands CCL19 and CCL21, and inhibits the activation of the ERK1/2 pathway. TC6-D3 reduces the migratory capacity of tumor cells in vitro. TC6-D3 inhibits tumor growth and lymph node metastasis in vivo. TC6-D3 restores T cell cytotoxicity, promotes CD8+ T cell infiltration, and enhances anti-tumor immune responses. TC6-D3 can be used in studies related to lymph node metastasis.
|
|
/
|
| HY-156263A | TB Medium Powder |
TB Medium Powder can be used to culture genetically engineered bacteria Escherichia coli and is rich in nutrients.
|
|
/
|
| HY-P992153 | Serrumab |
Serrumab is a human monoclonal antibody that counteracts the biochemical and immunological effects of Tityus serrulatus venom. Serrumab inhibits the TsV-induced increase in the production of IL-6, TNFα and IL-10. Serrumab also prevents TsV-induced elevations in plasma urea, creatinine, aspartate transaminase and glucose levels, as well as the TsV-induced increase in neutrophil recruitment. Serrumab can be used in research related to envenoming by the Brazilian yellow scorpion.
Species: Tityus serrulatus |
|
/
|
| HY-113221AS | Isovalerylcarnitine-d3 chloride |
Isovalerylcarnitine-d3 chloride is the deuterium labeled Isovalerylcarnitine chloride (HY-145542). Isovalerylcarnitine chloride is a metabolite of leucine. Isovalerylcarnitine chloride can specifically activate calpain in human neutrophils. Isovalerylcarnitine chloride inhibits tumor cell proliferation and induces apoptosis. Elevated circulating levels of Isovalerylcarnitine chloride are negatively correlated with reduced lung cancer risk.
|
|
/
|
| HY-P3305 | NBD-LLLLpY |
NBD-LLLLpY is an enzymatically forming intranuclear peptide for selectively killing human induced pluripotent stem cells.
|
|
/
|
| HY-N18241 | Hibiscolactone A |
Hibiscolactone A is a 2H-naphtho[2,3-b]furan-2-one derivative and a superoxide anion generation inhibitor, which can be isolated from the stems of Pachira aquatica. The IC50 value of Hibiscolactone A against fMLP (HY-P0224)-induced human neutrophil activity (inhibiting superoxide anion generation) is 63.22 μM.
|
|
/
|
| HY-P1813 | PSA1 (141-150) |
PSA1 (141-150), a prostate specific antigen 1 peptide, is used in the immunotherapy of cancer experiments.
|
|
/
|
| HY-P992518 | Pumitamig (Mouse IgG2a) |
Pumitamig (Mouse IgG2a) is the Mouse IgG2a control antibody for Pumitamig (HY-P991097). Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
|
|
/
|
| HY-W414069 | Thiocholesterol |
Thiocholesterol is a member of the class of cholesteric liquid crystals (CLCs) that can be used to synthesis cationic lipid. Thiocholesterol is a stronger stabilizer of silver nanoparticles (SNPs). Thiocholesterol can be used for plasma membrane research and drug delivery.
|
|
/
|
| HY-P992035 | AMY109 |
AMY109 is an anti-human interleukin-8 (IL-8) monoclonal antibody, with a Ka of 36.8 pM for human IL-8, and a Ka of 380 pM for cynomolgus monkey IL-8. AMY109 binds to human and cynomolgus monkey IL-8 in a pH-dependent manner, inhibits IL-8-mediated activation of CXCR1 and CXCR2, and blocks the downstream biological activities of IL-8. AMY109 inhibits neutrophil recruitment to endometriotic lesions and suppresses monocyte chemoattractant protein-1 production by neutrophils. AMY109 is applicable to research related to endometriosis.
Species: Human |
|
/
|
| HY-166973 | Polysarcosine 20 |
Polysarcosine 20 (pSar 20) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 20 can be used in drug delivery research.
|
|
/
|
| HY-P992051 | Anti-CD103 Antibody (hCD103.01A) |
Anti-CD103 Antibody (hCD103.01A) is a monoclonal antibody targeting human CD103 and can be used in cancer immunotherapy and immunological research. Recommend Isotype Controls: human IgG1 kappa, Isotype Control (HY-P99001).
Species: Human |
|
/
|
| HY-P992212 | Anti-CD62L Antibody (DREG-200) |
Anti-CD62L Antibody (DREG-200) is a human monoclonal antibody targeting CD62L/L-selectin. Anti-CD62L Antibody (DREG-200) binds to residues 45, 46 and 47 of L-selectin, and blocks L-selectin-mediated interactions, neutrophil rolling, adhesion, aggregation, secondary anchoring, as well as leukocyte rolling on ligands. Anti-CD62L Antibody (DREG-200) reduces myocardial necrosis, coronary endothelial dysfunction, and neutrophil migration driven by neutrophil microparticles. Anti-CD62L Antibody (DREG-200) exerts cardioprotective effects in feline models. Anti-CD62L Antibody (DREG-200) can be used in studies related to myocardial ischemia-reperfusion injury. The recommended isotype control is Mouse IgG1 kappa (HY-P99977).
Species: Human |
|
/
|
| HY-126675G | AS2863619 (GMP) |
AS2863619 GMP is AS2863619 (HY-126675) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. AS2863619 is an orally active CDK8/19 inhibitor that also inhibits BMP2, MDA5 and RIG-I receptors. AS2863619 targets Stat5a-CDK8/19 to promote the differentiation of CD4+ T cells into regulatory T cells and induce FOXP3 expression, thereby restoring immune homeostasis and establishing transplant immune tolerance. AS2863619 also enhances the BMP2/SMAD signaling pathway to promote osteogenic differentiation and inhibit adipogenic differentiation. AS2863619 exerts osteoprotective effects by alleviating inflammation-induced impairment of osteogenic function and inducing neutrophil apoptosis (apoptosis). AS2863619 can be applied to research in related fields such as periodontitis-induced bone defects.
|
|
/
|
| HY-P991997 | Anti-CD16a Antibody (3G8) |
Anti-CD16a Antibody (3G8) is a pan-CD16-specific antibody. Anti-CD16a Antibody (3G8) binds to an epitope overlapping with CD16a’s Fc binding site, inhibiting CD16a-IgG Fc region interactions.Anti-CD16a Antibody (3G8) recognizes CD16a, CD16b, and CD16b-NA1 and NA2 allelotypes expressed by neutrophils.
Species: Human |
|
/
|
| HY-125567 | Antileukinate |
Antileukinate, a hexapeptide, is a potent inhibitor of CXC-chemokine receptor (CXCR). Antileukinate inhibits neutrophil chemotaxis and activation. Antileukinate can be used for the research of acute inflammation and injury.
|
|
/
|
| HY-109541S1 | Colfosceril miristate-d4 |
Colfosceril miristate-d4 (DMPC-d4) is deuterium labeled Colfosceril miristate. Colfosceril miristate is a synthetic phospholipid used in liposomes. Colfosceril miristate is used to study lipid monolayers, bilayers and drug delivery.
|
|
/
|
| HY-D3274 | PE-Cy5 |
PE-Cy5 is a tandem fluorescent dye commonly used in flow cytometry, immunofluorescence, and cell biology research. It is formed by the covalent linkage of two fluorescent molecules, namely phycoerythrin and CY5. PE-Cy5 binds to human FcγRI (CD64), and this binding can be blocked by human pooled serum, anti-CD64 monoclonal antibodies targeting the ligand-binding region, or aggregated IgG. PE-Cy5 supports three-color flow cytometry analysis, and whole blood staining can partially reduce its non-specific binding (Ex/Em = 450-500 nm/665 nm).
|
|
/
|
| HY-P10947 | MACTIDE-V |
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206+ tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models.
|
|
/
|
| HY-N21974 | Moracin M 3'-O-β-D-glucopyranoside |
Moracin M 3'-O-β-D-glucopyranoside is a natural product with multiple activities such as hypoglycemic and antitumor effects. Moracin M 3'-O-β-D-glucopyranoside acts as an inhibitor of mushroom tyrosinase with an IC50 of 127.5 μM, and also functions as an inhibitor of soluble epoxide hydrolase with an IC50 of 7.7 μM. Moracin M 3'-O-β-D-glucopyranoside can be used in studies related to hyperglycemia and skin tumors.
|
|
/
|
| HY-109541S4 | Colfosceril miristate-d63 |
Colfosceril miristate-d63 (DMPC-d63) is deuterium labeled Colfosceril miristate. Colfosceril miristate a synthetic phospholipid used in liposomes. Colfosceril miristate is used to study lipid monolayers, bilayers and drug delivery.
|
|
/
|
| HY-P11140 | KSL-W |
KSL-W is a multifunctional antibacterial peptide with immune regulatory function. KSL-W has a chemotactic effect on neutrophils. KSL-W can induce neutrophil F-actin polymerization dependent on the Gαi protein signaling pathway. KSL-W can inhibit the production of reactive oxygen species (ROS) in neutrophils. KSL-W can be used for research on infection control and inflammation regulation.
|
|
/
|
| HY-143211 | Murapalmitine |
Murapalmitine is the component of liposomes for drug delivery.
|
|
/
|
| HY-P991634 | IBI-325 |
IBI-325 is a humanized monoclonal antibody inhibitor targeting CD73. IBI-325 completely inhibits CD73 enzymatic activity without hook effect. IBI-325 reverses Adenosine monophosphate (HY-A0181)-mediated immune suppression and significantly inhibits T cell proliferation and cytokines (IL-2, IFN-γ and TNF-α) release. IBI-325 has potent antitumor activities in hPBMC-reconstituted mice model and hCD73 knock-in mice model. IBI-325 can be used for cancer immunotherapy research.
Species: Human |
|
/
|
| HY-N17409 | Eupatobenzofuran |
Eupatobenzofuran is a dihydrobenzofuran derivative that can be found in the aerial part of Eupatorium cannabinum subsp. asiaticum. Eupatobenzofuran inhibits fMLP/CB-induced elastase release by human neutrophils with an IC50 value of 11.3 μM.
|
|
/
|
| HY-120333 | Antibiotic PF 1052 |
Antibiotic PF 1052 is an antibiotic extracted from a natural product library. Antibiotic PF 1052 has an inhibitory effect on murine neutrophil migration.
Source: Phoma sp. FKI-1840 |
|
/
|
| HY-P11186 | CALNN |
CALNN is a pentapeptide that can be used as a ligand to stabilise and functionalise gold nanoparticles in drug delivery systems.
|
|
/
|
| HY-116705G | 2-Deoxy-2-fluoro-L-fucose (GMP) |
2-Deoxy-2-fluoro-L-fucose (2-Fluorofucose) GMP is a fucosyltransferase inhibitor that inhibits core fucosylation modification in cells. 2-Deoxy-2-fluoro-L-fucose GMP promotes the production of defucosylated IgG1 antibodies in IgG1-expressing cell culture systems; it regulates the levels of inflammatory cytokines such as IL-1β, IL-6 and TGF-β in human induced pluripotent stem cell-derived microglia. 2-Deoxy-2-fluoro-L-fucose GMP can be used in the research of related diseases including dengue fever and Alzheimer's disease.
|
|
/
|
| HY-166994 | Heptyl 7-bromoheptanoate |
Heptyl 7-bromoheptanoate is a lipid that can be used in drug delivery studies.
|
|
/
|
| HY-145542S | Isovalerylcarnitine-d9 chloride |
Isovalerylcarnitine-d9 chloride is the deuterium labeled Isovalerylcarnitine chloride (HY-145542). Isovalerylcarnitine chloride is a metabolite of leucine. Isovalerylcarnitine chloride can specifically activate calpain in human neutrophils. Isovalerylcarnitine chloride inhibits tumor cell proliferation and induces apoptosis. Elevated circulating levels of Isovalerylcarnitine chloride are negatively correlated with reduced lung cancer risk.
|
|
/
|
| HY-D2734 | Heparin-Cy3 |
Heparin-Cy3 is a fluorescent dye composed of Cy3 (HY-D0822) and Heparin. Heparin-Cy3 can be used for cell tracing and drug delivery.
|
|
/
|
| HY-D2310 | CXCR2 Probe 1 |
|
/
|
|
| HY-20457G | TL8-506 (GMP) |
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy.
|
|
/
|
| HY-W724404 | N-Oleoyl serinol-d5 |
N-Oleoyl serinol-d5 (Oleoyl serinol-d5) is the deuterium labeled N-Oleoyl serinol (HY-122788). N-Oleoyl serinol is a ceramide analog that can be used in stem cell therapy to prevent stem cells from developing into teratomas. N-Oleoyl serinol induces apoptosis in residual pluripotent embryoid body-derived cells (EBCs), prevents teratoma formation, and enriches EBC cells that undergo neural differentiation after transplantation.
|
|
/
|
| HY-166974 | Polysarcosine 150 |
Polysarcosine 150 (pSar 150) is a hydrophilic alternative to PEG that has good targeted drug delivery properties and can remain in the bloodstream longer. Polysarcosine 150 can be used in drug delivery research.
|
|
/
|
| HY-P5631 | Rabbit neutrophil peptide 3b |
Rabbit neutrophil peptide 3b is an antimicrobial peptide derived from rabbit peritoneal neutrophils.
|
|
/
|
| HY-160453 | MC-Gly-Gly-Phe-Gly-NH-CH2-O-cyclopropane-CH2COOH |
MC-Gly-Gly-Phe-Gly-NH-CH2-O-cyclopropane-CH2COOH is a camptothecin derivative. MC-Gly-Gly-Phe-Gly-NH-CH2-O-cyclopropane-CH2COOH can be used for antibody drug conjugate (ADC).
|
|
/
|
| HY-13689G | Go 6983 (GMP) |
Go 6983 GMP is Go 6983 (HY-13689) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Go 6983 is a dual inhibitor targeting Suv39h1/2 (KMT1A/KMT1B) and PKC, as well as a transcriptional activator capable of inducing DNA hypomethylation. Go 6983 stimulates the transcription of Prdm14 by reducing Suv39h1/2 protein levels, decreasing histone modifications in the Prdm14 promoter region, and increasing the recruitment of RNA polymerase II. Go 6983 induces genome-wide DNA hypomethylation by inhibiting de novo methyltransferase expression and increasing Tet1/Tet2 levels, thereby promoting self-renewal and pluripotency maintenance of stem cells. Meanwhile, Go 6983 can block PKC-mediated signaling pathways to reduce the expression of EMT-related genes and eliminate the upregulation of antioxidant genes downstream of NRF2. Go 6983 is mainly used in mechanism studies related to myocardial ischemia/reperfusion injury.
|
|
/
|
| HY-D2620 | CAR-2 |
CAR-2 is a BODIPY-based photosensitizer that induces ferroptosis in photodynamic therapy (PDT) by targeting the endoplasmic reticulum (ER) and lipid droplets (LDs). CAR-2 exhibits phototoxicity in breast cancer cells with IC50 of 0.01-0.02 μM. CAR-2 exhibits antitumor efficacy in 4T1 xenograft mouse models.
|
|
/
|
| HY-12299G | WH-4-023 (GMP) |
WH-4-023 GMP is WH-4-023 (HY-12299) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. WH-4-023 (Dual LCK/SRC inhibitor) is a Lck/Src dual target inhibitor with functions in stem cell maintenance and differentiation regulation. WH-4-023 blocks epithelial-mesenchymal transition, supports the self-renewal of porcine embryonic stem cells, and inhibits their differentiation into mesoderm and endoderm. WH-4-023 is a key component of 3i/LAF medium, and enables the stable establishment and long-term maintenance of porcine pre-gastrulation epiblast stem cell lines. Removal of WH-4-023 reduces the expression of pluripotency factors in porcine and human extended pluripotent stem cells. WH-4-023 can be applied to relevant studies such as non-small cell lung cancer resistant to EGFR-TKIs.
|
|
/
|
| HY-14648S1 | Dexamethasone-d5-1 |
Dexamethasone-d5-1 is deuterium labeled Dexamethasone. Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
|
Exosomes
Isotope-Labeled Compounds
Glucocorticoid Receptor
SARS-CoV
Autophagy
Complement System
Mitophagy
Bacterial
Antibiotic
|
/
|
| HY-N0565AG | Doxycycline (hydrochloride) (GMP) |
Doxycycline hydrochloride GMP is Doxycycline (hydrochloride) (HY-N0565A) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Doxycycline hydrochloride is an orally active highly lipophilic, tissue-permeable MMP inhibitor with broad-spectrum antibacterial activity. Doxycycline hydrochloride is also a semi-synthetic antibiotic with chelating properties, which blocks bacterial protein synthesis and inhibits extracellular matrix degradation through interactions with zinc and calcium atoms. Doxycycline hydrochloride also inhibits mitochondrial biogenesis, translation, and the expression of respiratory chain proteins. Doxycycline hydrochloride induces apoptosis, inhibits autophagy and EMT, downregulates stem cell markers, and activates the PI3K-AKT pathway, thereby effectively inhibiting the viability and proliferation of cancer cells such as breast cancer cells. Doxycycline hydrochloride also promotes the survival and self-renewal of embryonic stem cells and neural stem cells, and reduces the frequency of medium changes in culture. Doxycycline hydrochloride has been applied in studies related to breast cancer, prostate cancer, bladder cancer, and other cancers.
|
Infection
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Breast Cancer
Prostate Cancer
Bladder Cancer
|
/
|
| HY-12273G | DMH-1 (GMP) |
DMH-1 (GMP) is GMP grade DMH-1 (HY-12273). DMH-1 (GMP) is a selective BMP inhibitor. DMH-1 (GMP) upregulates the expression of SOX1. DMH-1 (GMP) increases cardiomyocyte progenitor cells and promotes the differentiation of mouse embryonic stem cells into cardiomyocytes. DMH-1 (GMP) induces the differentiation of hiPSC-derived neural progenitor cells into β3-tubulin-positive neurons.
|
|
/
|
| HY-145782 | Witepsol |
Witepsol is a selective lipid-based vehicle for use in drug delivery systems.
|
|
/
|
| HY-15651S | Alvelestat-13C,d3 |
Alvelestat-13C,d3 (AZD9668-13C,d3) is the deuterated, 13C-labeled Alvelestat (HY-15651). Alvelestat (AZD9668) is an orally active, selective inhibitor of neutrophil elastase. Alvelestat reduces elastase activity, myeloperoxidase release, neutrophil recruitment and activation, and calcium phosphate precipitation; promotes smooth muscle cell colonization and collagen deposition; and inhibits the formation of neutrophil extracellular traps (NETs) as well as NET-derived neutrophil elastase activity. Alvelestat restores endothelial dysfunction, regulates antioxidant factors, improves the expression of endothelial tight junctions, reduces vascular leakage, and accelerates wound healing. Alvelestat prevents pulmonary hemorrhage, matrix protein degradation, airspace enlargement, and small airway wall remodeling; and alleviates cigarette-induced inflammatory responses. Alvelestat inhibits the growth of abdominal aortic aneurysms exacerbated by Porphyromonas gingivalis. Alvelestat can be used in research related to chronic obstructive pulmonary disease, abdominal aortic aneurysm, radiation-induced skin injury, and bronchiectasis.
|
|
/
|
| HY-W653978 | Cinacalcet-d4 hydrochloride |
Cinacalcet-d4 (AMG-073-d4) hydrochlorideis deuterium labeled Cinacalcet (hydrochloride). Cinacalcet hydrochloride (AMG-073 hydrochloride) is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease treatment.
|
|
/
|
| HY-N0442R | 5-O-Methylvisammioside (Standard) |
5-O-Methylvisammioside (4'-O-β-D-Glucosyl-5-O-methylvisamminol) (Standard) is the analytical standard of 5-O-Methylvisammioside. This product is intended for research and analytical applications. 5-O-Methylvisammioside is an orally active natural chromone glycoside and multiple biological activities. 5-O-Methylvisammioside inhibits ferroptosis by activating the Nrf2/HO-1 signaling axis. 5-O-Methylvisammioside alleviates intestinal barrier damage by inhibiting the ROS/NF-κB/NLRP3 pathway. 5-O-Methylvisammioside exerts a protective effect against acute liver injury by reducing ALT/AST, decreasing inflammatory infiltration, and inhibiting IκB-α phosphorylation and NF-κB nuclear translocation. 5-O-Methylvisammioside blocks the HMGB1/RAGE/MEK/ERK signaling axis to exert anti-tumor and anti-angiogenic effects. 5-O-Methylvisammioside improves depression-like behaviors by inhibiting Src kinase and the NF-κB pathway.
|
NF-κB
Ferroptosis
Reference Standards
TNF Receptor
VEGFR
Anaplastic lymphoma kinase (ALK)
JNK
Reactive Oxygen Species (ROS)
ERK
Amyloid-β
NOD-like Receptor (NLR)
p38 MAPK
MEK
Src
Cancer
Neurological, Eye or Ear Disease
Inflammation or Immune System Disease
Metabolic or Endocrine Disease
|
/
|
| HY-N2427R | Adamantane (Standard) |
Adamantane (Standard) is the analytical standard of Adamantane. This product is intended for research and analytical applications. Adamantane, a polycyclic cage molecule with high symmetry and remarkable properties. Adamantane can be incorporated into a lipophilic part of the lipid bilayer that constitutes membranes and as an anchor in the lipid bilayer of liposomes. Adamantane can be used in research of surface recognition and drug delivery.
|
|
/
|
| HY-N7131R | Coumarin 6 (Standard) |
Coumarin 6 (Standard) is the analytical standard of Coumarin 6 (HY-N7131). This product is intended for research and analytical applications. Coumarin 6, a fluorescent dye, is used as a fluorescent probe in a microparticle drug delivery system to conduct in vivo tracking, cell uptake, and transport mechanism studies of drug delivery systems (λexc=450 nm, λem=505 nm).
|
|
/
|
| HY-P991839 | Anti-CD19 Antibody (FMC63) |
Anti-CD19 Antibody (FMC63) is an antibody that binds to CD19, with a human Kd value ranging from 0.42 nM to 149 nM. Anti-CD19 Antibody (FMC63) mediates tumor cell killing, cytokine secretion, stable CAR expression, T cell activation and memory differentiation. Anti-CD19 Antibody (FMC63) fails to eliminate lymphoma cells carrying CD19 point mutations or co-expressing FMC63-CAR19, induces higher levels of activation-induced cell death, and reduces cell persistence. Anti-CD19 Antibody (FMC63) can be used in research related to B-cell non-Hodgkin's lymphoma, B-cell acute lymphoblastic leukemia, relapsed or refractory diffuse large B-cell lymphoma, etc.
Species: Human |
|
/
|
| HY-D2921 | BODIPY-FL-Vindoline |
BODIPY-FL-Vindoline is a high-affinity fluorescent probe for the pregnane X receptor (PXR), with a Kd of 256 nM. BODIPY-FL-Vindoline can be used in the research of drug metabolism and drug-drug interactions.
|
|
/
|
| HY-P5603 | Bovine neutrophil beta-defensin 12 |
Bovine neutrophil beta-defensin 12 is an antimicrobial peptide derived from bovine neutrophils, which has antibacterial activity against Escherichia coli and Staphylococcus aureus.
|
|
/
|
| HY-N0508R | Rosin (Standard) |
Rosin (Standard) is the analytical standard of Rosin (HY-N0508). This product is intended for research and analytical applications. Rosin is a natural oleoresin found in coniferous trees of the genus Pinus, such as Pinus massoniana. Rosin exhibits cholesterol-lowering, anti-gastric ulcer, anti-tumor, blood glucose-lowering, and anti-macrocyte aggregation activities. Rosin inhibits TPA (HY-18739)-induced EBV-EA activation and suppresses papilloma formation in a two-stage mouse skin carcinogenesis model. WBR, a processed product of Rosin, inhibits the IL-23/IL-17 inflammatory axis and reduces Th1 and Th17 cell infiltration. Rosin is used in research on psoriasis and skin cancer.
|
|
/
|
| HY-10475G | AM580 (GMP) |
|
/
|
|
| HY-D2401F1 | Cy5-Polystyrene microsphere (20um) |
Cy5-Polystyrene microsphere (20um) is a Cy5 (HY-D0821)-labeled microsphere that can be used for bioimaging and drug delivery.
|
|
/
|
| HY-P11094 | Tet1-Cys peptide |
Tet1-Cys peptide is a peptide with the sequence HLNILSTLWKYRC. Tet1 (HLNILSTLWKYR) (HY-P10998) can specifically bind to the neuronal ganglioside receptor GT1b, possessing neuronal targeting capabilities. The Tet1-Cys peptide sequence has an added Cys, which can be used for drug conjugation for research on drug delivery.
|
|
/
|
| HY-P991126 | Ciltistotug |
Ciltistotug is a monoclonal antibody targeting human CD40 (TNFRSF5). Ciltistotug activates immune cells after binding to CD40, exerting immunostimulatory and antitumor activities. Ciltistotug is promising for research of cancer immunotherapy.
Species: Human |
|
/
|
| HY-P3402 | HBpep-K |
HBpep-K is a peptide that can form co aggregated droplets. HBpep-K can efficiently load and deliver small peptides, proteins, and mRNA. HBpep-K can protect mRNA from RNase degradation. HBpep-K is commonly used for drug delivery.
|
|
/
|
| HY-P991125 | Cenzestotug |
Cenzestotug is a monoclonal antibody targeting human tumor necrosis factor receptor superfamily member 4 (TNFRSF4). Cenzestotug activates relevant immune cells by binding to TNFRSF4, exerting immunostimulatory and antitumor activities. Cenzestotug is promising for research of cancer immunotherapy.
Species: Human |
|
/
|
| HY-122767 | Romurtide |
|
/
|
|
| HY-P991149 | Nesfrotamig |
Nesfrotamig (YH32367; ABL105) is a bispecific activator targeting HER2 and 4-1BB. The Kd values of Nesfrotamig for human HER2 and human 4-1BB are 0.48 nM and 3.36 nM, respectively. By blocking tumor cell growth signals, activating HER2-dependent local 4-1BB in tumors to maintain T cell survival, and inducing NK cell-mediated antibody-dependent cellular cytotoxicity, Nesfrotamig enhances the cytotoxicity and tumor infiltration ability of immune cells. Nesfrotamig promotes the generation of tumor-specific memory T cells, drives T cell-mediated tumor lysis, exhibits significant anti-tumor efficacy against both HER2-positive and HER2-low-expressing tumors, and shows synergistic activity when combined with anti-PD-1 antibodies. In cynomolgus monkey studies, Nesfrotamig demonstrates good safety and is suitable for research related to HER2-positive and HER2-low-expressing tumors.
Species: Human |
|
/
|
| HY-P3402A | HBpep-K acetate |
HBpep-K acetate is a peptide that can form co aggregated droplets. HBpep-K acetate can efficiently load and deliver small peptides, proteins, and mRNA. HBpep-K acetate can protect mRNA from RNase degradation. HBpep-K acetate is commonly used for drug delivery.
|
|
/
|
| HY-W014989 | Thioglucose |
Thioglucose is a thiosugar with antioxidant properties. Thioglucose acts as an H2S/polysulfide donor to elevate intracellular sulfane sulfur levels and promote hydropersulfide formation. Thioglucose reduces the endocytosis of gold nanoparticles by phagocytes, enhances cytotoxicity and improves biocompatibility by increasing their adsorption on the surface of cancer cells. Thioglucose can be engineered into a stimulus-responsive prodrug or functional reagent for the development of targeted nanocarriers, and is used in studies related to human breast adenocarcinoma and cervical cancer.
|
|
/
|
| HY-N7032S | Uridine 5′-diphosphoglucose-13C disodium |
Uridine 5′-diphosphoglucose-13C (UDP-D-Glucose-13C) disodium is the 13C labeled Uridine 5′-diphosphoglucose disodium (HY-N7032). Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
|
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-109541S2 | Colfosceril miristate-d9 |
Colfosceril miristate-d9 (DMPC-d9) is deuterium labeled Colfosceril miristate. Colfosceril miristate a synthetic phospholipid used in liposomes. Colfosceril miristate is used to study lipid monolayers, bilayers and drug delivery.
|
|
/
|
| HY-D2441 | TAT-PEG-Cy3 |
TAT-PEG-Cy3 is a fluorescent labeling reagent that combines Cy3 fluorescent dye, Cell membrane penetrating peptide (TAT) and polyethylene glycol (PEG). The Cy3 fluorophore is commonly used in applications such as immunolabeling, nucleic acid labeling, fluorescence microscopy, and flow cytometry. Cy3 has an emission maximum around 562-570 nm. TAT-PEG-Cy3 can be used for cell targeted delivery and biological imaging.
|
|
/
|
| HY-P990689 | Zifibancimig |
Zifibancimig (RO-7250284) is a monoclonal antibody against VEGF-A and Ang-2, with affinities of 4 pM and 2 pM, respectively. Zifibancimig has high stability, maintains target-binding capability under physiological stress and storage conditions, and is designed for sustained long-term ocular delivery via the Port Delivery implant device. Zifibancimig can be used in the research of retinal diseases.
Species: Human |
|
/
|
| HY-N8541 | Endocrocin |
Endocrocin is an anthraquinone fungal secondary metabolite. Endocrocin inhibits the recruitment and migration of neutrophils, and enhances the pathogenicity and virulence of Fumagillin (HY-B0751) in Drosophila. Endocrocin can be used in research related to invasive aspergillosis, viral infections and liver diseases.
Source: Aspergillus fumigatus |
|
/
|
| HY-N7032S1 | Uridine 5′-diphosphoglucose-13C6 disodium |
Uridine 5′-diphosphoglucose-13C6 (UDP-D-Glucose-13C6) disodium is the 13C labeled Uridine 5′-diphosphoglucose disodium (HY-N7032). Uridine 5’-diphosphoglucose (UDP-glucose) disodium, secreted by cardiomyocytes during ischemia and reperfu, is a potent agonist of the proinflammatory P2Y14 receptor. It acts an important role in the regulation of inflammation and neutrophil polarization in neutrophils. Uridine 5’-diphosphoglucose disodium is also the precursor of glucose-containing oligosaccharides, polysaccharides, glycoproteins, and glycolipids in animal tissues and in some microorganisms. Uridine 5’-diphosphoglucose disodium is promising for research in counteracting myocardial infarction/reperfusion (MIR)-induced inflammation in the heart tissue.
|
Inflammation or Immune System Disease
Blood or Cardio-cerebrovascular Disease
Metabolic or Endocrine Disease
|
/
|
| HY-W654243 | Isovalerylcarnitine-d9-1 chloride |
|
/
|
|
| HY-D2401F | Cy5-Polystyrene microsphere (100nm) |
Cy5-Polystyrene microsphere (100 nm) is a Cy5 (HY-D0821)-labeled microsphere that can be used for bioimaging and drug delivery.
|
|
/
|
| HY-70037AS | Cinacalcet-d3 hydrochloride |
Cinacalcet-d3 (hydrochloride) is the deuterium labeled Cinacalcet (hydrochloride). Cinacalcet hydrochloride (AMG-073 hydrochloride) is an orally active, allosteric agonist of Ca receptor (CaR), used for cardiovascular disease treatment.
|
|
/
|
| HY-P10217 | PD-1/PD-L1-IN-42 |
PD-1/PD-L1-IN-42 (Compound B8.4) is an inhibitor of the interaction between PD-1 and PD-L1, with an EC50 of 0.1 μM. PD-1/PD-L1-IN-42 can be used for the research of cancer immunotherapy.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Ovarian Cancer
|
/
|
| HY-NP143 | Nerve Growth Factor 2.5S,murine submaxillary gland |
Nerve Growth Factor 2.5S,murine submaxillary gland is a neurotrophic polypeptide and protein growth factor isolated from murine submaxillary glands. Nerve Growth Factor 2.5S,murine submaxillary gland increases the survival rate, phagocytic capacity and superoxide anion production level of mouse cells. Nerve Growth Factor 2.5S,murine submaxillary gland acts through cell membrane surface receptors to mediate the differentiation and maintenance of adrenergic neurons in the sympathetic nervous system. Nerve Growth Factor 2.5S,murine submaxillary gland loses its activity and undergoes dimer dissociation due to oxidation; it remains active after modification of specific tryptophan residues, while its tyrosine residues are not essential for activity. Nerve Growth Factor 2.5S,murine submaxillary gland may play a role in the inflammatory process.
|
|
/
|
| HY-14648S5 | Dexamethasone-d3-1 |
Dexamethasone-d3-1 (Hexadecadrol-d3-1; Prednisolone F-d3-1) is a deuterium labeled Dexamethasone (HY-14648). Dexamethasone (Hexadecadrol) is a glucocorticoid receptor agonist. Dexamethasone also significantly decreases CD11b, CD18, and CD62L expression on neutrophils, and CD11b and CD18 expression on monocytes. Dexamethasone is highly effective in the control of COVID-19 infection. Dexamethasone inhibits production of exosomes containing inflammatory microRNA-155 in lipopolysaccharide-induced macrophage inflammatory responses.
|
Isotope-Labeled Compounds
Glucocorticoid Receptor
Mitophagy
Exosomes
Autophagy
ADC Payloads
Bacterial
Antibiotic
SARS-CoV
Complement System
|
/
|
| HY-P1118 | Ac9-25 |
Ac9-25, a N-terminal peptide of Annexin I, acts as a formyl peptide receptor (FPR) agonist and activates the neutrophil NADPH oxidase through FPR.
|
|
/
|
| HY-158217 | GelMA, 30% methacrylation, Green Fluorescent |
Green Fluorescent Gelatin Methacryloyl (Green Fluorescent GelMA) is methacryloyl gelatin (GelMA) with green fluorescence, which is obtained by "grafting" fluorescent molecules on GelMA. Green Fluorescent Gelatin Methacryloyl acts as a scaffold and can be used to engineer tissue analogs from the vasculature to cartilage and bone, allowing cells to proliferate and spread. GelMA, 30% methacrylation, Green Fluorescent needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
Application: cell culture, biological 3D printing, tissue engineering, etc. |
|
/
|
| HY-P991401 | GSK2862277 |
GSK2862277 is a human monoclonal antibody (mAb) targeting TNFRSF1A. GSK2862277 increases neutrophil extracellular trap formation and alveolar macrophage phagocytosis. GSK2862277 can be used in Acute lung injury and Acute Respiratory Distress Syndrome (ARDS) research. Recommended isotype control: VHH-hFc.
Species: Human |
|
/
|
| HY-P4866 | Q-Peptide |
Q-Peptide is an angiopoietin-1 derived peptide (QHREDGS). Q-Peptide interacts with β1-integrin, binds to integrins on the surface of osteoblasts, and serves as an acyl donor substrate for Streptomyces mobaraensis transglutaminase. Q-Peptide activates Akt, MAPKp42/44, ILK, ERK1/2, and downregulates caspase-3/7. Q-Peptide inhibits cell apoptosis, enhances cell adhesion and migration, and promotes osteoblast differentiation, bone matrix deposition and mineralization. Q-Peptide can be used in studies related to myocardial infarction, bone regeneration, diabetic wound repair and human induced pluripotent stem cells.
|
|
/
|
| HY-P990812 | Anti-Mouse myeloperoxidase/MPO Antibody (6D1) |
Anti-Mouse myeloperoxidase/MPO Antibody (6D1) is a mouse-derived IgG2b κ type antibody inhibitor, targeting to mouse Mouse myeloperoxidase/MPO. Anti-Mouse myeloperoxidase/MPO Antibody (6D1) can induce anti-neutrophil associated antibody (ANCA) mediated vasculitis in mice.
Species: Mouse |
|
/
|
| HY-P10862A | AH-D peptide TFA |
AH-D peptide TFA is an antiviral peptide that selectively disrupts membrane structures within the size range of exosomes, inducing T-EXO depletion and enhancing cancer immunotherapy.
|
|
/
|
| HY-109506R | DPPC (Standard) |
DPPC (Standard) is the analytical standard of DPPC. This product is intended for research and analytical applications. DPPC (129Y83) is a phosphoglyceride that can be used to prepare lipid monolayers, bilayers, and liposomes. DPPC is the main lipid component of pulmonary surfactant. Dppc-liposome can be effectively used as a delivery vector to induce an immune response against GSL antigen in mice.
|
|
/
|
| HY-P99825 | Relfovetmab |
|
/
|
|
| HY-P0266B | N-Acetyl-Ser-dAsp-Lys-Pro acetate |
N-Acetyl-Ser-dAsp-Lys-Pro (Ac-SdKP) acetate is a specific substrate for the N-terminal active site of angiotensin-converting enzyme (ACE). N-Acetyl-Ser-dAsp-Lys-Pro acetate is a natural inhibitor of pluripotent hematopoietic stem cell proliferation. Anti-inflammatory and antifibrotic properties.
|
|
/
|
| HY-N14001 | Naamidine J |
Naamidine J is an imidazole-type alkaloids discovered in a sponge. Naamidine J inhibits inflammation by binding to the protein CSE1L (KD = 5.41 μM). Namidine J significantly inhibits the expression of pro-inflammatory factors such as TNF-α, IL-1β, and IL-6, and upregulates anti-inflammatory factors such as CD206 and Arg-1. Namidine J inhibits PD-L1 and shows antitumor activity. Namidine J significantly reduces pulmonary tissue edema, inflammatory cell infiltration and cytokine storm in mice. Namidine J can be used for the research on the immune microenvironment of acute lung injury and tumors.
Source: Pericharax heteroraphis |
|
/
|
| HY-P3486 | GADGVGKSAL |
GADGVGKSAL is a mutant KRAS G12D 10mer peptide. GADGVGKSAL can be used as an immunogenic neoantigen for cancer immunotherapy research.
|
|
/
|
| HY-P10862 | AH-D peptide |
AH-D peptide is a brain-penetrant antiviral agent disrupting highly curved lipid membranes. AH-D peptide exhibits broad-spectrum antiviral activity against ZIKV, Dengue virus, Chikungunya virus, yellow fever virus and Japanese encephalitis virus, with
IC50 values of 11.9, 12.5, 35.7, 206 and 136 nM, respectively. AH-D peptide reduces the viral load in the brain, suppresses inflammation, protects neurons, and does not damage the blood brain barrier. AH-D peptide restores antitumor immunity by decreasing circulating PD-L1+ exosomes, reducing intratumoral immunosuppressive cells (regulatory T cells, myeloid-derived suppressor cells), and enhancing T cell function. AH-D peptide inhibits membrane-enveloped viruses and cancer cell metastasis in vivo. AH-D peptide exhibits no immunogenicity and has negligible effects on normal tissues. AH-D peptide can be used for research in Zika virus and other mosquito-borne viruses, cancer immunotherapy and metastasis. |
|
/
|
| HY-158218 | GelMA, 30% methacrylation, Red Fluorescent |
Red Fluorescent Gelatin Methacryloyl (Red Fluorescent GelMA) is methacryloyl gelatin (GelMA) with red fluorescence, which is obtained by "grafting" fluorescent molecules on GelMA. Red Fluorescent Gelatin Methacryloyl acts as a scaffold and can be used to engineer tissue analogs from the vasculature to cartilage and bone, allowing cells to proliferate and spread. GelMA, 30% methacrylation, Red Fluorescent needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
Application: cell culture, biological 3D printing, tissue engineering, etc. |
|
/
|
| HY-P3487 | GAGGVGKSA |
GAGGVGKSA is a wild type KRAS G12D 9mer peptide. GAGGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
|
|
/
|
| HY-D2841 | FITC-Heparin |
FITC-Heparin is a fluorescent dye composed of FITC (HY-66019) and Heparin. FITC-Heparin can be used for cell tracing and drug delivery.
|
|
/
|
| HY-P99834 | Crefmirlimab |
Crefmirlimab (IAB22M2C; ImaginAb) is a humanized CD8-specific single-domain antibody. Conjugation of Crefmirlimab with radioisotopes (e.g., 89Zr) enables tumor immune infiltration assessment, autoimmune disease detection, and immunotherapy response monitoring. Crefmirlimab is applicable for cancer research.
Species: Human |
|
/
|
| HY-158217A | GelMA, 60% methacrylation, Green Fluorescent |
Green Fluorescent Gelatin Methacryloyl (Green Fluorescent GelMA) is methacryloyl gelatin (GelMA) with green fluorescence, which is obtained by "grafting" fluorescent molecules on GelMA. Green Fluorescent Gelatin Methacryloyl acts as a scaffold and can be used to engineer tissue analogs from the vasculature to cartilage and bone, allowing cells to proliferate and spread. GelMA, 60% methacrylation, Green Fluorescent needs to self-assemble into fibrous hydrogel under the action of photoinitiator LAP (HY-44076), and target bioactive adhesion sites, play an inherent supporting role for tissue cells and biodegradable activity.
Application: cell culture, biological 3D printing, tissue engineering, etc. |
|
/
|
| HY-P99308 | Ocaratuzumab |
|
/
|
|
| HY-N1420AR | Rhamnose monohydrate (Standard) |
Rhamnose monohydrate (Standard) is the analytical standard of Rhamnose monohydrate (HY-N1420A). Rhamnose monohydrate (L-Rhamnose monohydrate) is an orally active deoxysugar. Rhamnose monohydrate can inhibit levels of pro-inflammatory interleukin and matrix metalloproteinases (MMPs) in skin aging models. Rhamnose can promote the phosphorylation levels of PKA substrates and HSL in SVF-derived adipocytes, stimulating PKA signaling. Rhamnose monohydrate can act against obesity in mice by stimulating fat dopamine receptors and inducing thermogenesis. Rhamnose monohydrate shows anti-aging effects. Rhamnose monohydrate can be used in the study of Ehrlich’s solid tumors and sarcomas.
|
|
/
|
| HY-P10424 | OPBP-1 |
OPBP-1 is a D-peptide obtained by phage display screening, molecular docking and molecular dynamics simulation. OPBP-1 has high stability and strong antitumor and oral activity. OPBP-1 can selectively bind PD-L1 protein, significantly block the interaction between PD-1 and PD-L1, and this blocking effect helps to restore and improve the function of T lymphocytes and reduce the proportion of bone marrow derived suppressor cells (MDSCs) to combat tumor-induced immune escape. OPBP-1 can be used in cancer immunotherapy research.
|
Lung Cancer
Breast Cancer
Colorectal Cancer
Gastric Cancer
Liver Cancer
Leukemia/Lymphoma/Myeloma
Ovarian Cancer
|
/
|
| HY-W004260R | Arachidic acid (Standard) |
Arachidic acid (Standard) is the analytical standard of Arachidic acid (HY-W004260). This product is intended for research and analytical applications. Arachidic acid (Eicosanoic acid) is a long-chain saturated fatty acid. Arachidic acid can be found in the human organism from the plasma phospholipid, fish, cannabis and other plant oils. Arachidic acid conjugated with Chitosan oligosaccharide (HY-112108) can be used for anti-cancer drug delivery research.
|
|
/
|
| HY-P3488 | GADGVGKSA |
GADGVGKSA is a mutant KRAS G12D 9mer peptide. GADGVGKSA can be used as an immunogenic neoantigen for cancer immunotherapy research.
|
|
/
|
| HY-N7885 | (25R)-Spirost-4-ene-3,12-dione |
(25R)-Spirost-4-ene-3,12-dione ((-)-(25R)-Spirost-4-ene-3,12-dione) is a natural product that has an inhibitory effect on neutrophil superoxide anion production and histamine release from mast cells.
|
|
/
|
| HY-W004260S4 | Arachidic acid-d4 |
Arachidic acid-d4 is the deuterium labeled Arachidic acid (HY-W004260). Arachidic acid (Eicosanoic acid) is a long-chain saturated fatty acid. Arachidic acid can be found in the human organism from the plasma phospholipid, fish, cannabis and other plant oils. Arachidic acid conjugated with Chitosan oligosaccharide (HY-112108) can be used for anti-cancer drug delivery research.
|
|
/
|
| HY-125527S | Resolvin D1-d5 |
Resolvin D1-d5 is the deuterium labeled Resolvin D1. Resolvin D1 (RvD1), an endogenous pro-resolving mediator of inflammation, is derived from omega-3 docosahexaenoic acid during the resolution phase of acute inflammation. Resolvin D1 blocks proinflammatory neutrophil migration by regulating actin polymerization, reduces TNF-α-mediated inflammation in macrophages, and enhances phagocytosis of apoptotic cells by macrophages.
|
|
/
|
| HY-P5533 | CRT |
CRT, an iron peptide mimic, can bind to apo-transferrin (apo-Tf). CRT can be used to modify nanoparticles, and enhances drug delivery efficiency.
|
|
/
|
| HY-P99238 | Rolinsatamab |
Rolinsatamab is a IgG1κ type chimeric antibody targeting to PRLR (prolactin receptor). Rolinsatamab can be conjugated with pyrrolobenzodiazepine (PDB) dimer SGD-1882 (HY-101127) via a cleavable maleimidocaproyl type linker, to form an antibody-drug conjugate, Rolinsatamab talirine. One Rolinsatamab talirine has an average of 2 site-specific drug attachment engineered cysteines (S239C). The linker equips the valine-alanine dipeptide, as cathepsine B cleavage site. on an average of 2 site-specific drug attachment engineered cysteines (S239C).
Species: Human |
|
/
|
| HY-P4047 | Cyclo(RGDfK(Mal)) |
Cyclo(RGDfK(Mal)) is a pentapeptide. Cyclo(RGDfK(Mal)) improves the attachment and infiltration of human pluripotent stem cells. Cyclo(RGDfK(Mal)) can be used for 3D stem cell culture and expansion.
|
|
/
|
| HY-W004260S2 | Arachidic acid-d3 |
Arachidic acid-d3 is the deuterium labeled Arachidic acid (HY-W004260). Arachidic acid (Eicosanoic acid) is a long-chain saturated fatty acid. Arachidic acid can be found in the human organism from the plasma phospholipid, fish, cannabis and other plant oils. Arachidic acid conjugated with Chitosan oligosaccharide (HY-112108) can be used for anti-cancer drug delivery research.
|
|
/
|
| HY-15147G | XAV-939 (GMP) |
XAV-939 (GMP) is XAV-939 (HY-15347) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. XAV-939 is a tankyrase inhibitor.
|
|
/
|
| HY-13418G | Dorsomorphin dihydrochloride (GMP) |
Dorsomorphin dihydrochloride (GMP) is the GMP level of Dorsomorphin dihydrochloride (HY-13418). GMP guidelines are used to produce Dorsomorphin dihydrochloride (GMP). GMP small molecules works appropriately as an auxiliary reagent for cell research manufacture. Dorsomorphin dihydrochloride (GMP) is a potent, selective and ATP-competitive AMPK inhibitor. Dorsomorphin dihydrochloride (GMP) can be used for the research of induced differentiation of pluripotent stem cells (PSCs).
|
|
/
|
| HY-166979 | Stearic acid-mPEG2000 |
Stearic acid-mPEG2000 is a PEG lipid that can improve the delivery efficiency and tissue specificity of poorly soluble drugs. Stearic acid-mPEG2000 can be used in drug delivery research.
|
|
/
|
| HY-P0261A | Indolicidin acetate |
Indolicidin acetate is a potent antimicrobial peptide purified from the cytoplasmic granules of bovine neutrophils.
|
|
/
|
| HY-P11058 | OVA(250-264) |
OVA(250-264) (OVAvac) (OVAp) is an antigen peptide that can be from ovalbumin (OVA) presented by the class I MHC molecule, H-2Kb. OVA(250-264) combined withαMSLN (anti-MSLN antibody) significantly induces antigen-specific CD8+ T cell generation and infiltration for enhancing antitumor efficacy in orthotopic pancreatic cancer mice model. OVA(250-264) can be used for neoantigen vaccine development in pancreatic cancer immunotherapy research.
|
|
/
|
| HY-P990130 | Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26) |
Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26) is a mouse-derived IgG2a κ type antibody, targeting to mouse/rat CD71/TfR1. Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26) targets the transferrin receptor and binds to an extracellular domain for the transferrin receptor. Anti-Mouse/Rat CD71/TfR1 Antibody (OX-26) can be used for the research in drug delivery, especially for drug delivery to the brain.
Species: Mouse/Rat |
|
/
|
| HY-W004260S1 | Arachidic acid-d39 |
Arachidic acid-d39 is the deuterium labeled Arachidic acid (HY-W004260). Arachidic acid (Eicosanoic acid) is a long-chain saturated fatty acid. Arachidic acid can be found in the human organism from the plasma phospholipid, fish, cannabis and other plant oils. Arachidic acid conjugated with Chitosan oligosaccharide (HY-112108) can be used for anti-cancer drug delivery research.
|
|
/
|
| HY-P990651 | PY314 |
PY314 is a humanized antibody targeting TREM2. PY314 binds TREM2 on tumor-associated macrophages, depletes TREM2-high tumor-associated macrophages, reduces pro-tumorigenic M2 macrophage infiltration, increases CD8+ T cell, NK cell, and M1 macrophage infiltration, creates a proinflammatory tumor microenvironment, and promotes antitumor immune responseS. PY314 can be used for the research of platinum-resistant ovarian cancer, advanced solid tumors, breast cancer, and advanced refractory solid tumors.
Species: Human |
|
/
|
| HY-P10950A | PD-L1 inhibitory peptide TFA |
PD-L1 inhibitory peptide TFA is an inhibitor targeting the PD-1/PD-L1 interaction. PD-L1 inhibitory peptide TFA inhibits the PD-1-mediated apoptosis signaling pathway, maintains the survival and activity of T cells, activates the anti-tumor effect of cytotoxic T lymphocytes, and significantly improves the survival rate of mice in fungal sepsis models. PD-L1 inhibitory peptide TFA can be used for research on sepsis, breast cancer and other related diseases, as well as immunotherapy.
|
|
/
|
| HY-145542 | Isovalerylcarnitine chloride |
Isovalerylcarnitine chloride is a metabolite of leucine. Isovalerylcarnitine chloride can specifically activate calpain in human neutrophils. Isovalerylcarnitine chloride inhibits tumor cell proliferation and induces apoptosis. Elevated circulating levels of Isovalerylcarnitine chloride are negatively correlated with reduced lung cancer risk.
|
|
/
|
| HY-P99950 | Evorpacept |
Evorpacept (ALX148) is a high-affinity CD47-blocking fusion protein with an inactive human immunoglobulin Fc region. Evorpacept binds to CD47, blocks the interaction of the CD47-SIRPα immune checkpoint, and inhibits the binding of wild-type SIRPα to CD47. Evorpacept is applicable to research related to acute myeloid leukemia.
|
|
/
|
| HY-P4486 | H-Pro-Gly-Pro-OH |
H-Pro-Gly-Pro-OH is a collagen-derived matrikine that has classically been described as a neutrophil chemoattractant. H-Pro-Gly-Pro-OH is perfectly positioned to focus neutrophils on the site required and direct a localized repair response. H-Pro-Gly-Pro-OH activates the transcription of neurotrophins and their receptor genes after cerebral ischemia.
|
|
/
|
| HY-N0442 | 5-O-Methylvisammioside |
5-O-Methylvisammioside (4'-O-β-D-Glucosyl-5-O-methylvisamminol) is an orally active natural chromone glycoside and multiple biological activities. 5-O-Methylvisammioside inhibits ferroptosis by activating the Nrf2/HO-1 signaling axis. 5-O-Methylvisammioside alleviates intestinal barrier damage by inhibiting the ROS/NF-κB/NLRP3 pathway. 5-O-Methylvisammioside exerts a protective effect against acute liver injury by reducing ALT/AST, decreasing inflammatory infiltration, and inhibiting IκB-α phosphorylation and NF-κB nuclear translocation. 5-O-Methylvisammioside blocks the HMGB1/RAGE/MEK/ERK signaling axis to exert anti-tumor and anti-angiogenic effects. 5-O-Methylvisammioside improves depression-like behaviors by inhibiting Src kinase and the NF-κB pathway.
|
NF-κB
p38 MAPK
JNK
Src
TNF Receptor
NOD-like Receptor (NLR)
Amyloid-β
MEK
ERK
Ferroptosis
VEGFR
Anaplastic lymphoma kinase (ALK)
Reactive Oxygen Species (ROS)
|
/
|
| HY-P5506 | C5a Receptor agonist, W5Cha |
C5a Receptor agonist, W5Cha (Peptide 1) is a synthetic C5a receptor hexapeptide agonist. C5a Receptor agonist, W5Cha exhibits a IC50 of 0.07 μM for binding to C5a receptor on human neutrophil membranes. C5a Receptor agonist, W5Cha activates wild-type C5a receptor and induces Ca2+ flux. C5a Receptor agonist, W5Cha can be used in studies related to neutrophil activation and inflammation.
|
|
/
|
| HY-P99757 | Nivatrotamab |
Nivatrotamab (Hu3F8-BsAb) is a bispecific antibody targeting GD2 and CD3, with KD values of 5.8 nM and 194 nM, respectively. Nivatrotamab redirects T cells to tumor sites and activates immune synapses, thereby mediating antibody-dependent T cell-mediated cytotoxicity. Nivatrotamab induces specific tumor cytotoxicity, stimulates the release of Th1 cytokines and promotes immune cell infiltration into tumors. In addition, its Fc segment deglycosylation design effectively prevents complement activation and cytokine storm. Nivatrotamab can be widely used in research related to various solid tumors, including melanoma, neuroblastoma, osteosarcoma, small cell lung cancer, breast cancer, Ewing's sarcoma, colon cancer, ovarian cancer and rhabdomyosarcoma.
Species: Human |
|
/
|
| HY-P990858 | Anti-CD47 Antibody (B6.H12) |
Anti-CD47 Antibody (B6.H12) is a kind of mouse IgG1 κ chimeric antibody, targeting to human CD47. Anti-CD47 Antibody (B6.H12) blocks CD47 interactions with SIRPα. Anti-CD47 Antibody (B6.H12) inhibits cell proliferation, cell migration and invasion. Anti-CD47 Antibody (B6.H12) increases macrophage phagocytosis. Anti-CD47 Antibody (B6.H12) shows potent anti-tumor effect in various tumor models, such as osteosarcoma.
Species: Human |
|
/
|
| HY-P990245 | Anti-Mouse FAP Antibody (73.3) |
|
/
|
|
| HY-P990033 | Anzurstobart |
Anzurstobart (CC-95251; BMS-986351) is a CD47/SIRPα inhibitor with human SIRPα Kd of 0.0541 nM and human SIRPα IC50 of 100 nM. Anzurstobart binds SIRPα at a CD47-overlapping site, blocks CD47-SIRPα interactions, inhibits CD47-SIRPα axis signaling, and binds across 6 prevalent human SIRPα haplotypes. Anzurstobart binds SIRPγ and inhibits CD47-SIRPγ interactions. Anzurstobart can be used for the research of non-Hodgkin's lymphoma, colorectal cancer, squamous cell carcinoma of the head and neck, diffuse large B-cell lymphoma, and advanced solid and hematologic malignancies.
Species: Human |
|
/
|
| HY-P99313 | Quilizumab |
Quilizumab (Anti-Human IGHE Recombinant Antibody; 47H4; MEMP1972A) is a monoclonal antibody that targets FcγRIIIa and the M1 prime segment of human membrane-bound IgE. Quilizumab has enhanced FcγRIIIa binding affinity and activity against IgE class-switched B cells, and reduces serum IgE levels by inducing antibody-dependent cell-mediated cytotoxicity and apoptosis through cross-linking of membrane-bound IgE receptors. Quilizumab depletes IgE-producing cells; it also directly binds the membrane-bound M1 prime domain on IgE class-switched cells to inhibit IgE production. Quilizumab is used in research on allergic asthma and allergic diseases (asthma, allergic rhinitis).
Species: Human |
|
/
|
| HY-P990608 | Alpitatug |
Alpitatug (IMC 3C5) is a fully human monoclonal antibody and also a VEGFR3 inhibitor. Alpitatug blocks renal lymphangiogenesis, prevents the formation of tubulointerstitial lymphatic vessels, and reduces the number of lymphatic vessels in rats. Alpitatug does not alter the proteinuria level, inflammatory cell infiltration, fibrosis markers or renal function parameters in proteinuric rats. Alpitatug can be used in research related to proteinuric nephropathy and advanced solid tumors.
Species: Human |
|
/
|
| HY-P99175 | KWAR 23 |
KWAR23 is an anti-human SIRPα antibody. KWAR23 binds human SIRPα with high affinity and disrupts its binding to CD47. KWAR23 shows antitumor activity in combination with tumor-opsonizing antibodies and can be used in cancer immunotherapy research.
Species: Human |
|
/
|
| HY-P990132 | Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) |
Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an anti-mouse/rat/human CD47/IAP IgG1 monoclonal antibody. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can effectively block CD47 signaling and enhance macrophage phagocytic function. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can increase the infiltration of immune cells. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) may interfere with wound healing. Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) can be used for researches on cancer and inflammation conditions such as breast cancer and intestinal mucosal repair.
Species: Human/Mouse/Rat |
|
/
|
| HY-P99125 | Anti-Mouse CD16/CD32 Antibody (2.4G2) |
Anti-Mouse CD16/CD32 Antibody (2.4G2) is an anti-mouse CD16/CD32 IgG2b monoclonal antibody. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block Fcγ receptor-mediated immune responses. Anti-Mouse CD16/CD32 Antibody (2.4G2) can block the combination of CD16 and FcγRs to reduce the production of foam cells. Anti-Mouse CD16/CD32 Antibody (2.4G2) can be used for researches on atherosclerosis and autoimmune hematological disorders.
Species: Mouse |
|
/
|
| HY-13012G | RepSox (GMP) |
|
/
|
|
| HY-P990091 | Riliprubart |
Riliprubart (SAR 445088) is a selective anti-C1s humanized IgG4 monoclonal antibody with mutations that enhance its binding to the neonatal Fc receptor. Riliprubart blocks activation of the classical complement pathway, prevents the formation of the C3 convertase C4b2a, and inhibits complement-mediated hemolytic activity. Riliprubart can be used in research related to classical complement-mediated diseases, cold agglutinin disease, and chronic inflammatory demyelinating polyneuropathy. For the isotype control of Riliprubart, refer to Human IgG4 (S228P) kappa, Isotype Control (HY-P99003).
Species: Human |
|
/
|
| HY-Y0651 | Sodium sulfite |
Sodium sulfite is an inorganic salt used as an antioxidant and preservative. Sodium sulfite is also used in sulfonation and sulfomethylation reactions. Sodium sulfite can also be used as a bleaching agent, desulfurizer, and dechlorinator. Sodium sulfite inhibits hepatocyte proliferation, promotes hepatocyte apoptosis and necrosis, and impairs mitochondrial integrity. Sodium sulfite induces superoxide anion production, primes neutrophils for enhanced superoxide anion generation, and induces neutrophil gene expression. Sodium sulfite can be used in studies related to pulmonary inflammation and gastric tissue injury.
|
|
/
|
| HY-P991097 | Pumitamig |
Pumitamig (PM-8002, BNT-327) is a bispecific antibody targeting PD-L1 and VEGF-A, with immune activation and anti-angiogenic activities. By binding to PD-L1, Pumitamig restores the function of effector T cells, while neutralizing VEGF-A in the tumor microenvironment to reverse its inhibition on the infiltration and activation of immune cells and normalize tumor blood vessels. Pumitamig can also be combined with various ADCs targeting TROP2, B7H3, HER2, HER3 for the research of advanced/metastatic solid tumors, including non-small cell lung cancer, ovarian cancer, triple-negative breast cancer, cervical cancer, etc. Pumitamig also exhibits potential efficacy in "cold" tumors with low PD-L1 expression that are insensitive to immunotherapy.
Species: Human |
|
/
|
| HY-P990106 | Anti-Mouse VEGFR-2 Antibody (DC101) |
Anti-Mouse VEGFR-2 Antibody (DC101) is a rat anti-mouse VEGFR2 monoclonal antibody. Anti-Mouse VEGFR-2 Antibody (DC101) inhibits tumor angiogenesis by blocking the binding of VEGF and VEGFR2. Anti-Mouse VEGFR-2 Antibody (DC101) promotes immune cell infiltration and induces tumor cell apoptosis. Anti-Mouse VEGFR-2 Antibody (DC101) can be used for researches on various types of cancer such as melanoma, lung cancer and breast cancer .
Species: Mouse |
|
/
|
| HY-W020780 | mPEG5000-Mal |
mPEG5000-Mal (mPEG5000-Maleimide) is a PEG-derived selective covalent binding agent for sulfhydryl groups (RSGs), which can form irreversible thioether bonds with sulfhydryl groups under near-neutral conditions via the maleimide group. The mechanism of action of mPEG5000-Mal can be divided into two categories: firstly, as an enzyme modifier, it binds to target proteins through hydrophobic interactions, hydrogen bonds, and van der Waals forces, altering the protein's secondary structure; secondly, as a nanoparticle surface modifier, it covalently binds to sulfhydryl groups on the surface of red blood cells, changing the surface properties and morphology of the red blood cells, leading to their phagocytosis by macrophages of the reticuloendothelial system. mPEG5000-Mal can react with free cysteine in proteins, increasing the apparent molecular weight of the modified protein by 10-15 kDa for detection purposes. mPEG5000-Mal can enhance the thermal stability and catalytic activity of enzymes, and improve the macrophage targeting of nanoparticles, enabling targeted drug delivery. mPEG5000-Mal can be applied in enzyme engineering research in the food industry and in oncology, assisting radiotherapy by inhibiting tumor-associated macrophage infiltration and enhancing anti-tumor immune responses.
|
|
/
|
| HY-10431G | SB-431542 (GMP) |
SB-431542 (GMP) is SB-431542 (HY-10431) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. SB-431542 is a TGF-β receptor kinase inhibitor (TRKI) in SMAD signaling.
|
|
/
|
| HY-P99009 | Batoclimab |
Batoclimab (RVT-1401) is a fully humanized IgG1 monoclonal antibody targeting FcRn. Batoclimab has high affinity for the IgG-binding site on FcRn. By competitively binding to the IgG binding site on FcRn, Batoclimab blocks FcRn-mediated recycling of IgG, resulting in enhanced degradation and subsequent reductions in IgG levels. Batoclimab can be used in the research of autoimmune diseases such as myasthenia gravis and thyroid eye disease.
Species: Human |
|
/
|
| HY-134816 | D-Glucan |
D-Glucan is an orally effective Dectin-1 receptor immune activator with antioxidant properties (reducing TNF-α). D-Glucan activates macrophages and neutrophils to scavenge free radicals, inhibit oxidative stress and inflammatory responses, and improve insulin sensitivity. D-Glucan promotes glycolysis by enhancing the activity of the antioxidant enzyme glutathione, inhibiting gluconeogenesis and activating GK. D-Glucan can be used in the research of liver damage protection (antagonizing Acetaminophen (HY-66005) toxicity), radiation protection (synergistic with vitamin E) and diabetes (improving glucose metabolism).
|
|
/
|
| HY-147305 | Efgartigimod alfa |
Efgartigimod alfa (ARGX-113) is a reversibility, humanized Fc receptor antagonist . Efgartigimod alfa is a anti FcRn monoclonal immunoglobulin G (IgG1) Fc fragment. Efgartigimod reduces serum levels of total IgG, including pathogenic autoantibodies, by blocking FcRn function without permanent impairment. Efgartigimod alfa can be used for generalised myasthenia gravis (gMG) and primary immune thrombocytopenia research.
Species: Human |
|
/
|
| HY-P72179 | ELANE Protein, Human (GST) |
ELANE is a serine protease that critically regulates natural killer cells, monocytes, and granulocytes by inhibiting C5a-dependent neutrophil enzyme release and chemotaxis, thereby shaping immune responses. It also inhibits pyroptosis by cleaving GSDMB, affecting the regulation of programmed cell death. ELANE Protein, Human (GST) is the recombinant human-derived ELANE protein, expressed by E. coli , with N-GST labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P73808 | MMP-8 Protein, Mouse (HEK293) |
MMP-8 protein degrades different fibrillar collagens, such as type I, II, and III.It is implicated in the breakdown of collagen fibers during uterine involution.MMP-8 Protein, Mouse (HEK293) is the recombinant mouse-derived MMP-8 protein, expressed by HEK293 , with tag free.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P76220 | CD3 zeta/CD247 Protein, Human (His) |
CD3 zeta/CD247 is a component of the TCR-CD3 complex and can transmit APC-induced TCR signals to initiate immune responses. CD3D, CD3E, CD3G, and CD3Z contain ITAMs that are phosphorylated by LCK and FYN upon TCR engagement, providing docking sites for ZAP70. CD3 zeta/CD247 Protein, Human (His) is the recombinant human-derived CD3 zeta/CD247 protein, expressed by E. coli , with N-His labeled tag.
Species: Human; Source: E. coli |
|
/
|
| HY-P73298 | MMP-8 Protein, Human (HEK293) |
MMP-8, also known as matrix metalloproteinase-8 or collagenase-2, is recognized for its enzymatic abilities, particularly its ability to break down fibrillar types I, II, and III collagen. This enzymatic activity suggests that MMP-8 plays an important role in the remodeling and turnover of collagen-rich tissues such as connective tissue, cartilage, and bone. MMP-8 Protein, Human (HEK293) is the recombinant human-derived MMP-8 protein, expressed by HEK293 , with N-Met labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P70049 | CXADR Protein, Human (HEK293, His) |
CXADR proteins are components of the epithelial apical junction complex and, as cell adhesion molecules, are critical for the integrity of tight junctions. CXADR Protein, Human (HEK293, His) is the recombinant human-derived CXADR protein, expressed by HEK293 , with C-6*His labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P72364 | CXADR Protein, Mouse (Biotinylated, HEK293, Avi-His) |
CXADR protein is a key component of the epithelial apical junction complex, which maintains the integrity of tight junctions and enables leukocyte migration through adhesive interactions with JAML. This interaction activates γ-δ T cells and promotes tissue repair through cell signaling involving PI3 kinase and MAP kinase. CXADR Protein, Mouse (Biotinylated, HEK293, Avi-His) is the recombinant mouse-derived CXADR protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P74655 | p67phox Protein, Human (sf9, His-GST) |
p67phox is central to the activation of NADPH oxidase, which is critical for superoxide production. p67phox forms heterodimers with CYBA and CYBB and interacts with NCF4 and NCF1 to establish important connections within the complex. p67phox Protein, Human (sf9, His-GST) is the recombinant human-derived p67phox protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P76870 | DEFA3/Defensin alpha 3 Protein, Human (HEK293, Fc) |
The DEFA3/defensin alpha 3 protein is a potent effector in innate immunity against a variety of infectious agents, including bacteria, fungi, and viruses. It neutralizes bacterial toxins, such as Bacillus anthracis lethal factor and Staphylococcus aureus leukocidin, and plays a key role in blocking herpes simplex virus infection by preventing viral attachment. DEFA3/Defensin alpha 3 Protein, Human (HEK293, Fc) is the recombinant human-derived DEFA3/Defensin alpha 3 protein, expressed by HEK293 , with N-hFc labeled tag.
Species: Human; Source: HEK293 |
|
/
|
| HY-P7720 | Carbonic Anhydrase 4 Protein, Human (His) |
Carbonic Anhydrase 4 Protein, Human (His) a recombinant Mouse Carbonic Anhydrase 4 produced in E. coli, has a His tag at the N-terminus. The Carbonic Anhydrase 4 (CA4) protein is a zinc metalloenzyme that catalyzes the reversible hydration and dehydration of CO2 and HCO3-.
Species: Human; Source: E. coli |
|
/
|
| HY-P705506 | AOAH Protein, Human (His) |
Species: Human; Source: E. coli |
|
/
|
| HY-P72054 | RCVRN Protein, Human (sf9, His-Myc) |
The RCVRN protein is a calcium sensor that regulates phototransduction in cone and rod photoreceptors, enhancing the light sensitivity of cone photoreceptors in dark conditions. Under low light, it prolongs RHO/rhodopsin activation in rod photoreceptor cells by inhibiting GRK1-mediated phosphorylation. RCVRN Protein, Human (sf9, His-Myc) is the recombinant human-derived RCVRN protein, expressed by sf9 insect cells , with N-10*His, C-Myc labeled tag.
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P7717 | Carbonic Anhydrase 4 Protein, Mouse (HEK293, His) |
Carbonic Anhydrase 4 Protein, Mouse (HEK293, His), a recombinant human CAMK1 produced in HEK293 cells, has a His tag at the N-terminus. The Carbonic Anhydrase 4 (CA4) protein is a zinc metalloenzyme that catalyzes the reversible hydration and dehydration of CO2 and HCO3-.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P71778 | RCVRN Protein, Human (P.pastoris, His) |
The RCVRN protein is a calcium sensor that regulates phototransduction in cone and rod photoreceptors, enhancing the light sensitivity of cone photoreceptors in dark conditions. Under low light, it prolongs RHO/rhodopsin activation in rod photoreceptor cells by inhibiting GRK1-mediated phosphorylation. RCVRN Protein, Human (P.pastoris, His) is the recombinant human-derived RCVRN protein, expressed by P. pastoris , with N-His labeled tag.
Species: Human; Source: P. pastoris |
|
/
|
| HY-P73809 | MMP-8 Protein, Mouse (CHO, His) |
MMP-8 protein degrades different fibrillar collagens, such as type I, II, and III.It is implicated in the breakdown of collagen fibers during uterine involution.MMP-8 Protein, Mouse (CHO, His) is the recombinant mouse-derived MMP-8 protein, expressed by CHO , with C-His labeled tag.
Species: Mouse; Source: CHO |
|
/
|
| HY-P74656 | p67phox Protein, Human (sf9) |
p67phox is central to the activation of NADPH oxidase, which is critical for superoxide production. p67phox forms heterodimers with CYBA and CYBB and interacts with NCF4 and NCF1 to establish important connections within the complex. p67phox Protein, Human (sf9) is the recombinant human-derived p67phox protein, expressed by Sf9 insect cells, with tag free and with additional two amino acids (Gly & Pro) at the N-terminus.
Species: Human; Source: Sf9 insect cells |
|
/
|
| HY-P706228 | CXADR Protein, Mouse (HEK293, His, hFc) |
CXADR protein is a key component of the epithelial apical junction complex, which maintains the integrity of tight junctions and enables leukocyte migration through adhesive interactions with JAML. This interaction activates γ-δ T cells and promotes tissue repair through cell signaling involving PI3 kinase and MAP kinase. CXADR Protein, Mouse (HEK293, His, hFc) is the recombinant mouse-derived CXADR protein, expressed by HEK293 , with His and hFc labeled tag.
Species: Mouse; Source: HEK293 |
|
/
|
| HY-P705628 | Papain Protein, Papaya (His) |
Species: Others; Source: E. coli |
|
/
|
| HY-P81215 | Neutrophil Elastase Antibody (YA3528) |
|
/
|
|
| HY-P81179 | CXCL5 Antibody (YA3504) |
CXCL5 Antibody (YA3504) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CXCL5.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P811005 | Phospho-p47 phox (Ser370) Antibody |
Phospho-p47 phox (Ser370) Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Phospho-p47 phox (Ser370).
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P811075 | Phospho-p47 phox (Ser304) Antibody |
Phospho-p47 phox (Ser304) Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Phospho-p47 phox (Ser304).
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P811106 | p47 phox Antibody |
p47 phox Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to p47 phox.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P811121 | Phospho-p47 phox (Ser345) Antibody |
Phospho-p47 phox (Ser345) Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Phospho-p47 phox (Ser345).
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P84004 | Neutrophil Elastase Antibody (YA3701) |
|
/
|
|
| HY-P811127 | Recoverin Antibody |
Recoverin Antibody is a Rabbit-derived and non-conjugated IgG Polyclonal antibody, targeting to Recoverin.
Host: Rabbit; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P86831 | CaSR Antibody (YA6524) |
|
/
|
|
| HY-P81179A | CXCL5 Antibody (YA3504)(PBS only) |
CXCL5 Antibody (YA3504) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to CXCL5.
Host: Rabbit; Reactivity: Human |
|
/
|
| HY-P84004A | Neutrophil Elastase Antibody (YA3701)(PBS only) |
|
/
|
|
| HY-P88151 | NR1I3 Antibody (YA7835) |
NR1I3 Antibody (YA7835) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to NR1I3.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P88151A | NR1I3 Antibody (YA7835)(PBS only) |
NR1I3 Antibody (YA7835) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to NR1I3.
Host: Mouse; Reactivity: Human |
|
/
|
| HY-P88593 | SPG7 Antibody (YA8277) |
SPG7 Antibody (YA8277) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to SPG7.
Host: Mouse; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-P88593A | SPG7 Antibody (YA8277)(PBS only) |
SPG7 Antibody (YA8277) is a Mouse-derived and non-conjugated IgG2a monoclonal antibody, targeting to SPG7.
Host: Mouse; Reactivity: Human, Mouse, Rat |
|
/
|
| HY-K0224 | Amino Magnetic Beads (200 nm, 10 mg/mL) |
MCE Amino magnetic beads (200 nm,10 mg/mL) can easily and efficiently combine with a variety of biological ligand in high loads, such as proteins, peptides, oligonucleotides, drug molecules, etc. It can be used as a good basic material for subsequent processing, adsorption, chemical modification and other follow-up processing. |
|
/
|
| HY-K0239 | Streptavidin-Binding Peptide Tag Agarose |
MCE Streptavidin-Binding Peptide Tag Agarose is composed of a highly cross-linked 4% agarose matrix with an engineered streptavidin mutant protein chemically immobilized onto the matrix in a highly oriented and high-density manner. It is suitable for the efficient purification of recombinant proteins carrying a streptavidin-binding peptide tag from a variety of expression systems, including E.coli, yeast, insect cells, and mammalian cells. |
|
/
|
| HY-K0359 | Human Neutrophil Negative Selection Kit |
MCE Human Neutrophil Negative Selection Kit can isolate neutrophils from fresh peripheral blood. The principle involves using biotin-labeled monoclonal antibodies to label non-target cells, followed by the removal of these non-target cells through streptavidin-labeled magnetic beads, achieving the selective isolation of human neutrophils. |
|
/
|
| HY-K1043A | Polyamine Supplement (1000×) |
MCE Polyamine Supplement (1000×) can be used as a component of the CEPT Cocktail in combination with Emricasan, Chroman 1, and trans-ISRIB to enhance the survival of pluripotent stem cells (PSCs) and promote single-cell clonal expansion. In addition, this supplement improves the viability of PSCs and their differentiated derivatives during cryopreservation, organoid culture, single-cell cloning, and genome editing, thereby enhancing the robustness and reproducibility of downstream applications. |
|
/
|
| HY-K2004 | Trypan Blue Staining Solution (0.4%) |
MCE Trypan Blue Staining Solution (0.4%) is suitable for viability assessment of most adherent and suspension cell lines. It is commonly used for cell culture quality control, evaluation of cellular responses following drug treatment, and viability measurements after cell thawing and recovery. |
|
/
|
| HY-K2033 | OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) |
MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology to achieve highly efficient nucleic acid(eg. pDNA、mRNA、sgRNA、siRNA) delivery into Jurkat cells. It is designed for in vitro transfection of Jurkat cells and is well suited for applications in immunotherapy, tumor immunology, and other immune cell-related research. |
|
/
|
| HY-K2034 | OptiLNP Antibody-ctLNP RNA Transfection Reagent (Human Primary T Cells) |
MCE OptiLNP Antibody-ctLNP pDNA Transfection Reagent (Jurkat Cells) utilizes antibody-conjugated cell-targeted lipid nanoparticle (Cell-targeted Lipid Nanoparticle, ctLNP) technology and is specifically optimized for human primary T cells. It enables efficient and targeted RNA delivery, improving transfection efficiency in difficult-to-transfect primary T cells. The kit is ideally suited for applications including CAR-T and TCR-T cell engineering, cancer immunology research, immune cell engineering, and in vitro T cell functional studies. |
|
/
|
| HY-K2035 | Fluc mRNA (N1-Me-pUTP) |
MCE Fluc mRNA (N1-Me-pUTP) is widely used for evaluating lipid nanoparticle (LNP) delivery efficiency, validating mRNA transfection reagents, assessing in vitro and in vivo mRNA expression, IVIS bioluminescence imaging, and screening novel nucleic acid delivery systems. It is commonly used as a positive control or reporter mRNA. |
|
/
|
| HY-K3022 | Recombinant Human Serum Albumin Solution (rHSA, 20%) |
MCE Recombinant Human Serum Albumin Solution (rHSA, 20%) can be widely used in various cell culture systems and is particularly suitable for maintaining the undifferentiated growth and expansion of human embryonic stem cells (hESC) and induced pluripotent stem cells (hiPSC) under both feeder-dependent and feeder-free conditions. |
|
/
|
| HY-K6019 | Stem Cell Cryopreservation Medium |
MCE Stem Cell Cryopreservation Medium is a ready-to-use, serum-free Cryopreservation Medium optimized for human pluripotent stem cells (PSCs). PSCs preserved with this medium exhibit high post-thaw viability (> 90%) and stable expression of pluripotency markers such as OCT4 and NANOG, providing consistent and reliable cell sources for subsequent expansion and differentiation. This product is suitable for long-term, stable storage of PSCs and downstream applications. |
|
/
|
| HY-K6020 | iPSC/ESC Dissociation Solution (Enzyme-Free) |
MCE iPSC/ESC Dissociation Solution (Enzyme-Free) is a chelation-based, enzyme-free cell dissociation reagent specifically designed for the culture and manipulation of induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs). This optimized solution enables gentle and efficient dissociation of iPSCs/ESCs within 5-8 min, making it suitable for routine passaging, dissociation, and cell-cluster handling. It provides superior stability and better preservation of cell state compared with traditional methods. |
|
/
|
| HY-K6021 | CEPT Cocktail Plus (1000×) |
MCE CEPT Cocktail Plus (1000×) is a composite supplement specifically formulated for pluripotent stem cell culture. Through synergistic effects, it inhibits oxidative damage, blocks apoptotic pathways, and regulates protein translation, significantly reducing cellular stress levels through multiple targets. This dramatically improves the survival rate and cloning efficiency of pluripotent stem cells. |
|
/
|
| HY-K6024 | Stem Cell Basement Membrane Matrix (Ready-to-Use) |
MCE Stem Cell Basement Membrane Matrix (Ready-to-Use) is pre-diluted using an optimized formulation and requires no additional dilution or preparation. It is designed for direct use in stem cell culture applications, including cell attachment, expansion, and pluripotency maintenance, and is suitable for the culture and differentiation of hESCs, iPSCs, and other pluripotent stem cells. |
|
/
|
| HY-K6305 | Human PSC Islet Organoid Differentiation Kit |
MCE Human PSC Islet Organoid Differentiation Kit enables the efficient directed differentiation of human pluripotent stem cells (PSCs) into structurally intact and functionally mature islet organoids within 26 d. |
|
/
|
| HY-K6501 | Human PSC Maintenance Medium |
MCE Human PSC Maintenance Medium is a ready-to-use, chemically defined formulation designed to support the robust growth and self-renewal of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) under feeder-free culture conditions. |
|
/
|
| HY-K6502 | Human iPSC-Derived Brain Organoid Long-term Culture Medium |
MCE Human iPSC-Derived Brain Organoid Long-term Culture Medium is a specialized culture system developed through systematic reformulation and concentration optimization based on neuronal cell culture platforms. It significantly enhances the adaptability and stability of long-term culture for brain organoids derived from human induced pluripotent stem cells (iPSCs). |
|
/
|
| HY-K6503 | Human PSC Embryoid Body (EB) Induction Medium |
MCE Human PSC Embryoid Body (EB) Induction Medium is specifically designed to support the efficient and reproducible formation of uniform embryoid bodies from pluripotent stem cells under suspension culture conditions. This optimized culture system integrates microenvironmental regulation with metabolic adaptation strategies, significantly improving the stability and reproducibility of EB formation. |
|
/
|
| HY-KE8011 | Phi29 DNA Polymerase(mutant) |
Phi29 DNA polymerase is a protein-engineered Phi29 DNA polymerase expressed in E. coli and then purified and isolated multiple times. Compared with wild-type Phi29 DNA polymerase, it has higher amplification efficiency and sensitivity, and can greatly shorten the reaction time. |
|
/
|
Targets/Pathways


























































.jpg)













































































































































































